

DEX-0117

BA



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68	A1	(11) International Publication Number: WO 00/06776 (43) International Publication Date: 10 February 2000 (10.02.00)
<p>(21) International Application Number: PCT/US99/16675</p> <p>(22) International Filing Date: 22 July 1999 (22.07.99)</p> <p>(30) Priority Data: 60/094,391 28 July 1998 (28.07.98) US</p> <p>(71) Applicant (for all designated States except US): AXYS PHARMACEUTICALS, INC. [US/US]; 180 Kimball Way, South San Francisco, CA 94080 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GALVIN, Margaret [US/US]; 7768 Corte Promenade, Carlsbad, CA 92009 (US). MILLER, Andrew [US/US]; 2131 Old Stone Mill Drive, Cranbury, NJ 08512 (US). PENNY, Laura [US/US]; 3903 Falcon Street, San Diego, CA 92103 (US). RIEDY, Michael [US/US]; 4066 Gresham Street #B, San Diego, CA 92109 (US).</p> <p>(74) Agent: SHERWOOD, Pamela, J.; Bozicevic, Field & Francis LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
<p>(54) Title: GENOTYPING HUMAN UDP-GLUCURONOSYLTRANSFERASE 2B4 (UGT2B4), 2B7 (UGT2B7) AND 2B15 (UGT2B15) GENES</p>		
<p>(57) Abstract</p> <p>Genetic polymorphisms are identified in the human UGT2B4, UGT2B7 and UGT2B15 genes that alter UGT2B activity. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and <i>in vitro</i> models for drug metabolism.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENOTYPING HUMAN UDP-GLUCURONOSYLTRANSFERASE 2B4 (UGT2B4), 2B7
(UGT2B7) and 2B15 (UGT2B15) GENES

INTRODUCTION

5 The metabolic processes commonly involved in the biotransformation of xenobiotics have been classified into functionalization reactions (phase I reactions), in which lipophilic compounds are modified via monooxygenation, dealkylation, reduction, aromatization, or hydrolysis. These modified molecules can then be substrates for the phase II reactions, often called conjugation reactions, as they conjugate a functional group with a polar,
10 endogenous compound. Drug glucuronidation, a major phase II conjugation reaction in the mammalian detoxification system, is catalyzed by the UDP-glucuronosyltransferases (UGTs) (Batt AM, et al. (1994) Clin Chim Acta 226:171-190; Burchell et al. (1995) Life Sci. 57:1819-31).

 The UGTs are a family of enzymes that catalyze the glucuronic acid conjugation of
15 a wide range of endogenous and exogenous substrates including phenols, alcohols, amines and fatty acids. The reactions catalyzed by UGTs permit the conversion of a large range of toxic endogenous/xenobiotic compounds to more water-soluble forms for subsequent excretion (Parkinson A (1996) Toxicol Pathol 24:48-57).

 The UGT isoenzymes are located primarily in hepatic endoplasmic reticulum and
20 nuclear envelope (Parkinson A (1996) Toxicol Pathol 24:48-57), though they are also expressed in other tissues such as kidney and skin. UGTs are encoded by a large multigene superfamily that has evolved to produce catalysts with differing but overlapping substrate specificities. Three families, UGT1, UGT2, and UGT8, have been identified within the superfamily. UGTs are assigned to one the subfamilies based on amino acid sequence
25 identity, e.g., UGT1 family members have greater than 45% amino acid sequence identity (Mackenzie et al. (1997) Pharmacogenetics 7:255-69).

 A single gene encodes several human UGT1 isoforms, the substrate specificity of each of which is thought to arise from differential splicing of a number of substrate-specific 5-prime regions of a single mRNA transcript to a shared 3-prime portion. On the other hand,
30 members of the mammalian UGT2 gene subfamily, which encode the odorant and steroid-metabolizing isoforms, show nucleotide differences in sequence throughout the length of the cDNAs. This suggested that the UGT2 isoenzymes are encoded by several independent genes. The UGT2 genes have been further divided on the basis of their tissue-specific expression patterns into the UGT2A gene subfamily, which encodes

olfactory-specific isoforms, and the UGT2B gene subfamily, which encodes steroid-metabolizing isoforms in the liver. Monaghan *et al.* (1994) Genomics 23:496-499 mapped the UGT2B9 and the UGT2B15 genes to chromosome 4q13, giving a provisional ordering of the genes as UGT2B9-UGT2B4-UGT2B15. The UGT2B subfamily contains
5 phenobarbital-inducible genes, as well as numerous genes that are constitutively expressed and are involved in the glucuronidation of endogenous steroids and biogenic amines (Mackenzie, *et al. supra.*) Evidence suggests that UGT2B4 is exclusively expressed in human liver, and not in human kidney. Levesque *et al.* (1997) Pharmacogenetics 7:317; and Coffman *et al.* (1997) Drug Metabol. and Dispos. 25:1-4, describe UGT2B gene
10 polymorphisms.

Alteration of the expression or function of UGTs may affect drug metabolism. For example, there may be common polymorphisms in the human UGT2B gene that alter expression or function of the protein product and cause drug exposure-related phenotypes. Thus, there is a need in the field to identify UGT2B polymorphisms in order to provide a
15 better understanding of drug metabolism and the diagnosis of drug exposure-related phenotypes.

SUMMARY OF THE INVENTION

Genetic sequence polymorphisms are identified in the UGT2B4, UGT2B7 and
20 UGT2B15 genes, herein generically referred to as "UGT2B genes". Nucleic acids comprising the polymorphic sequences are used in screening assays, and for genotyping individuals. The genotyping information is used to predict an individuals' rate of metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects. Specific polynucleotides include the polymorphic UGT2B4 sequences set forth in SEQ ID NOs:25-38;
25 the polymorphic UGT2B7 sequences set forth in SEQ ID NOs:84-111; and the polymorphic UGT2B15 sequences set forth in SEQ ID NOs:147-164.

The nucleic acid sequences of the invention may be provided as probes for detection of UGT2B locus polymorphisms, where the probe comprises a polymorphic sequence of SEQ ID NOs:25-38; 84-111 and 147-164. The sequences may further be utilized as an
30 array of oligonucleotides comprising two or more probes for detection of UGT2B locus polymorphisms.

Another aspect of the invention provides a method for detecting in an individual a polymorphism in UGT2B metabolism of a substrate, where the method comprises analyzing the genome of the individual for the presence of at least one UGT2B polymorphism; wherein

the presence of the predisposing polymorphism is indicative of an alteration in UGT2B expression or activity. The analyzing step of the method may be accomplished by detection of specific binding between the individual's genomic DNA with an array of oligonucleotides comprising UGT2B locus polymorphic sequences. In other embodiments, the alteration in
5 UGT2B expression or activity is tissue specific, or is in response to a UGT2B modifier that induces or inhibits UGT2B expression.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

UGT2B Reference Sequences. SEQ ID NOs: 1-6 list the sequence of the reference
10 UGT2B4 exons, where exon 1 is SEQ ID NO:1, exon 2 is SEQ ID NO:2 and so forth. Partial sequence of the flanking introns is included; the boundaries are annotated in the SEQLIST. The cDNA sequence is set forth in SEQ ID NO:7, and the encoded amino acid sequence in SEQ ID NO:8.

SEQ ID NO:39 lists the sequence of the UGT2B7 cDNA sequence, the encoded
15 polypeptide is provided in SEQ ID NO:40. SEQ ID NOs: 41-45 list the sequence of the reference UGT2B7 exons, where exon 1 is SEQ ID NO:41, exon 2 is SEQ ID NO:42 and so forth. Partial sequence of the flanking introns is included; the boundaries are annotated in the SEQLIST.

SEQ ID NO:112 lists the sequence of the UGT2B15 cDNA sequence, the encoded
20 polypeptide is provided in SEQ ID NO:113. SEQ ID NOs:114-118 list the sequence of the reference UGT2B15 exons, where exon 1 is SEQ ID NO:114, exon 2 is SEQ ID NO:115 and so forth. Partial sequence of the flanking introns is included; the boundaries are annotated in the SEQLIST.

Primers. The PCR primers for amplification of polymorphic sequences are set forth
25 as SEQ ID NOs:9-14; 46-66; and 135-146. The primers used in sequencing isolated polymorphic sequences are presented as SEQ ID NOs:15-24; 67-83; and 119-134.

Polymorphisms. Polymorphic sequences of UGT2B4 are presented as SEQ ID NOs:25-38. Polymorphic sequences of UGT2B7 are presented as SEQ ID NOs:84-111. Polymorphic sequences of UGT2B15 are presented as SEQ ID NO:147-164.

30

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Pharmacogenetics is the association between an individual's genotype and that individual's ability to metabolize or react to a therapeutic agent. Differences in metabolism or target sensitivity can lead to severe toxicity or therapeutic failure by altering the relation
5 between bioactive dose and blood concentration of the drug. Relationships between polymorphisms in metabolic enzymes or drug targets and both response and toxicity can be used to optimize therapeutic dose administration.

Genetic polymorphisms are identified in the UGT2B4, UGT2B7 and UGT2B15 genes. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered
10 metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell culture and *in vitro* cell-free models for drug metabolism.

15 Definitions

It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present
20 invention which will be limited only by the appended claims.

As used herein the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a construct" includes a plurality of such constructs and reference to "the UGT2B nucleic acid" includes reference to one or more nucleic acids and equivalents thereof known to those skilled in the art, and
25 so forth. All technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs unless clearly indicated otherwise.

UGT2B4 reference sequence. The sequence of human UGT2B4 cDNA may be
30 accessed through Genbank, accession number Y00317, and is provided in SEQ ID NOs:1-7.

The amino acid sequence of UGT2B4 is listed as SEQ ID NO:8. The sequence of human UGT2B7 may be accessed through Genbank, accession number 600068, and in the SEQLIST as described above. The sequence of human UGT2B15 may be accessed through Genbak, accession number 600069, and in the SEQLIST as described above. The

nucleotide sequences provided herein differ from the published sequence at certain positions throughout the sequence. Where there is a discrepancy the provided sequence is used as a reference.

5 The term "wild-type" may be used to refer to the reference coding sequences of UGT2B4, UGT2B7 and UGT2B15, and the term "variant", or "UGT2B" to refer to the provided variations in the UGT2B sequences. The UGT2B4, UGT2B7 and UGT2B15 sequences are generically referred to as "UGT2B", and may be further distinguished by the species, *e.g.* human, mouse, *etc.*, or by the specific gene number, *e.g.* UGT2B4, UGT2B7, *etc.* Where there is no published form, such as in the intron sequences, the term wild-type
10 may be used to refer to the most commonly found allele. It will be understood by one of skill in the art that the designation as "wild-type" is merely a convenient label for a common allele, and should not be construed as conferring any particular property on that form of the sequence.

15 *UGT2B polymorphic sequences.* It has been found that specific sites in the UGT2B4, UGT2B7 and UGT2B15 genes sequence are polymorphic, *i.e.* within a population, more than one nucleotide (G, A, T, C) is found at a specific position. Polymorphisms may provide functional differences in the genetic sequence, through changes in the encoded polypeptide, changes in mRNA stability, binding of transcriptional and translation factors to
20 the DNA or RNA, and the like. The polymorphisms are also used as single nucleotide polymorphisms (SNPs) to detect genetic linkage to phenotypic variation in activity and expression of the particular UGT2B protein.

SNPs are generally biallelic systems, that is, there are two alleles that an individual may have for any particular marker. SNPs, found approximately every kilobase, offer the
25 potential for generating very high density genetic maps, which will be extremely useful for developing haplotyping systems for genes or regions of interest, and because of the nature of SNPs, they may in fact be the polymorphisms associated with the disease phenotypes under study. The low mutation rate of SNPs also makes them excellent markers for studying complex genetic traits.

30 SNPs are provided in the UGT2B4, UGT2B7 and UGT2B15 intron and exon sequences. Tables 4, 7 and 10, and the corresponding sequence listing, provide both forms of each polymorphic sequence. For example, SEQ ID NO:37 and 38 are the alternative forms of a single polymorphic site. The provided sequences also encompass the complementary sequence corresponding to any of the provided polymorphisms.

In order to provide an unambiguous identification of the specific site of a polymorphism, sequences flanking the polymorphic site are shown in the tables, where the 5' and 3' flanking sequence is non-polymorphic, and the central position, shown in bold, is variable. It will be understood that there is no special significance to the length of non-polymorphic flanking sequence that is included, except to aid in positioning the polymorphism in the genomic sequence. The UGT2B exon sequences have been published, and therefore one of each pair of the sequences from exons in Tables 4, 7 and 10 are publically known sequence. The intron sequence has not been published, and hence both forms of this polymorphic sequence is novel.

As used herein, the term "UGT2B4, UGT2B7 and UGT2B15 genes" is intended to generically refer to both the wild-type and variant forms of the sequence, unless specifically denoted otherwise. As it is commonly used in the art, the term "gene" is intended to refer to the genomic region encompassing the 5' UTR, exons, introns, and the 3' UTR. Individual segments may be specifically referred to, *e.g.* exon 2, intron 5, *etc.* Combinations of such segments that provide for a complete UGT2B protein may be referred to generically as a protein coding sequence.

Nucleic acids of interest comprise the provided UGT2B^v nucleic acid sequence(s), as set forth in Tables 4, 7 and 10. Such nucleic acids include short hybridization probes, protein coding sequences, variant forms of UGT2B cDNA, segments, *e.g.* exons, introns, *etc.*, and the like. Methods of producing nucleic acids are well-known in the art, including chemical synthesis, cDNA or genomic cloning, PCR amplification, *etc.*

For the most part, DNA fragments will be of at least 15 nt, usually at least 20 nt, often at least 50 nt. Such small DNA fragments are useful as primers for PCR, hybridization screening, *etc.* Larger DNA fragments, *i.e.* greater than 100 nt are useful for production of the encoded polypeptide, promoter motifs, *etc.* For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art.

The UGT2B nucleic acid sequences are isolated and obtained in substantial purity, generally as other than an intact or naturally occurring mammalian chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include a UGT2B sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

For screening purposes, hybridization probes of the polymorphic sequences may be used where both forms are present, either in separate reactions, spatially separated on a solid phase matrix, or labeled such that they can be distinguished from each other. Assays may utilize nucleic acids that hybridize to one or more of the described polymorphisms.

5 An array may include all or a subset of the polymorphisms listed in Tables 4, 7 and 10. One or both polymorphic forms may be present in the array, for example the polymorphism of SEQ ID NO:37 and 38 may be represented by either, or both, of the listed sequences. Usually such an array will include at least 2 different polymorphic sequences, *i.e.* polymorphisms located at unique positions within the locus, and may include all of the
10 provided polymorphisms. Arrays of interest may further comprise sequences, including polymorphisms, of other genetic sequences, particularly other sequences of interest for pharmacogenetic screening, *e.g.* UGT1, other UGT2 sequences, cytochrome oxidase polymorphisms, *etc.* The oligonucleotide sequence on the array will usually be at least about 12 nt in length, may be the length of the provided polymorphic sequences, or may extend
15 into the flanking regions to generate fragments of 100 to 200 nt in length. For examples of arrays, see Ramsay (1998) Nat. Biotech. 16:40-44; Hacia *et al.* (1996) Nature Genetics 14:441-447; Lockhart *et al.* (1996) Nature Biotechnol. 14:1675-1680; and De Risi *et al.* (1996) Nature Genetics 14:457-460.

Nucleic acids may be naturally occurring, *e.g.* DNA or RNA, or may be synthetic
20 analogs, as known in the art. Such analogs may be preferred for use as probes because of superior stability under assay conditions. Modifications in the native structure, including alterations in the backbone, sugars or heterocyclic bases, have been shown to increase intracellular stability and binding affinity. Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are
25 substituted with sulfur; phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH₂-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage.

Sugar modifications are also used to enhance stability and affinity. The α -anomer
30 of deoxyribose may be used, where the base is inverted with respect to the natural β -anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O- methyl or 2'-O-allyl sugars, which provides resistance to degradation without compromising affinity.

Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'- deoxycytidine and

5-bromo-2'-deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

5 *UGT2B polypeptides.* A subset of the provided nucleic acid polymorphisms in UGT2B exons confer a change in the corresponding amino acid sequence. Using the amino acid sequence provided in SEQ ID NO:8 as a reference for UGT2B4, the amino acid polymorphisms of the invention include lys→asn, pos. 40; and glu→asp, pos. 454. Using the amino acid sequence provided in SEQ ID NO:40 as a reference for UGT2B7, the amino acid
10 polymorphisms of the invention include leu→phe, pos. 107; thr→ile, pos. 179; and lys→gln, pos. 430. Using the amino acid sequence provided in SEQ ID NO:125 as a reference for UGT2B15, the amino acid polymorphisms of the invention include ser→gly, pos. 15; asp→tyr, pos. 85; leu→pro, pos. 170; his→gln, pos. 282; ala→val, pos. 398; val→ile, pos. 443; and thr→lys, pos. 523.

15 Polypeptides comprising at least one of the provided polymorphisms (UGT2B^v polypeptides) are of interest. The term "UGT2B^v polypeptides" as used herein includes complete UGT2B protein forms, e.g. such splicing variants as known in the art, and fragments thereof, which fragments may comprise short polypeptides, epitopes, functional domains; binding sites; etc.; and including fusions of the subject polypeptides to other
20 proteins or parts thereof. Polypeptides will usually be at least about 8 amino acids in length, more usually at least about 12 amino acids in length, and may be 20 amino acids or longer, up to substantially the complete protein.

 The UGT2B4, UGT2B7 and UGT2B15 genetic sequences, including polymorphisms, may be employed for polypeptide synthesis. For expression, an expression cassette may
25 be employed, providing for a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region. Various transcriptional initiation regions may be employed that are functional in the expression host. The polypeptides may be expressed in prokaryotes or
30 eukaryotes in accordance with conventional ways, depending upon the purpose for expression. Small peptides can also prepared by chemical synthesis.

Substrate. A substrate is a chemical entity that is modified by UGT2B4, UGT2B7 or UGT2B15, usually under normal physiological conditions. Although the duration of drug action tends to be shortened by metabolic transformation, drug metabolism is not "detoxification". Frequently the metabolic product has greater biologic activity than the drug
5 itself. In some cases the desirable pharmacologic actions are entirely attributable to metabolites, the administered drugs themselves being inert. Likewise, the toxic side effects of some drugs may be due in whole or in part to metabolic products.

Substrates can be either endogenous substrates, *i.e.* substrates normally found within the natural environment of UGT2B, such as estriol, or exogenous, *i.e.* substrates that
10 are not normally found within the natural environment of UGT2B. UGT2B catalyzes glucuronidation of its substrates. The enzymes are specific for UDP-glucuronic acid, and not other UDP sugars.

Exemplary UGT2B4 substrates (*i.e.*, substrates of wild-type UGT2B4 and/or UGT2B4^v polypeptides) include, but are not necessarily limited to estriol and the catechol
15 estrogens 4-hydroxyestrone, and 2-hydroxyestriol, 2-aminophenol, 4-methylumbelliferone, 1-naphthol, 4-hydroxybiphenyl and 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl, menthol, *etc.*, among other substrates (Burchell *et al.* (1991) DNA Cell Biol 10:487-494, Jin CJ, *et al.* (1993) Biochem Biophys Res Commun 194:496-503).

Exemplary UGT2B7 substrates (*i.e.*, substrates of wild-type UGT2B7 and/or
20 UGT2B7^v polypeptides) include, but are not necessarily limited to oxazepam, hyodeoxycholic acid, estriol, S-naproxen, ketoprofen, ibuprofen, fenoprofen, clofibric acid (Patel *et al* (1995) Pharmacogenetics 5(1):43-49), morphine (Coffman *et al* (1997) Drug Metabolism and Disposition 25:1-4), DMXAA (5,6-dimethylxantheonone-4-acetic acid) (Miners *et al* (1997) Cancer Res 57:284), 2-Hydroxy AAF, 4 methylumbelliferone, carboxylic acid drugs (BP-7,8-
25 trans diol) (Burchell *et al.*, *supra.*)

Exemplary UGT2B15 substrates (*i.e.*, substrates of wild-type UGT2B15 and/or UGT2B15^v polypeptides) include, but are not necessarily limited to 4-hydroxybiphenyl, 1-naphthol, 4 methylumbelliferone , naringenin, eugenol (Burchell *et al.*, *supra.*), simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones; endogenous
30 estrogens and androgens (Green *et al.* (1994) Drug Metabolism and Disposition 22:799.

Modifier. A modifier is a chemical agent that modulates the action of a UGT2B molecule, either through altering its enzymatic activity (enzymatic modifier) or through

modulation of expression (expression modifier, e.g., by affecting transcription or translation). In some cases the modifier may also be a substrate.

Pharmacokinetic parameters. Pharmacokinetic parameters provide fundamental data for designing safe and effective dosage regimens. A drug's volume of distribution, clearance, and the derived parameter, half-life, are particularly important, as they determine the degree of fluctuation between a maximum and minimum plasma concentration during a dosage interval, the magnitude of steady state concentration and the time to reach steady state plasma concentration upon chronic dosing. Parameters derived from *in vivo* drug administration are useful in determining the clinical effect of a particular UGT2B genotype.

Expression assay. An assay to determine the effect of a sequence polymorphism on UGT2B expression. Expression assays may be performed in cell-free extracts, or by transforming cells with a suitable vector. Alterations in expression may occur in the basal level that is expressed in one or more cell types, or in the effect that an expression modifier has on the ability of the gene to be inhibited or induced. Expression levels of a variant alleles are compared by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β -galactosidase, luciferase, chloramphenicol acetyltransferase, etc. that provides for convenient quantitation; and the like.

Gel shift or electrophoretic mobility shift assay provides a simple and rapid method for detecting DNA-binding proteins (Ausubel, F.M. *et al.* (1989) In: Current Protocols in Molecular Biology, Vol. 2, John Wiley and Sons, New York). This method has been used widely in the study of sequence-specific DNA-binding proteins, such as transcription factors. The assay is based on the observation that complexes of protein and DNA migrate through a nondenaturing polyacrylamide gel more slowly than free DNA fragments or double-stranded oligonucleotides. The gel shift assay is performed by incubating a purified protein, or a complex mixture of proteins (such as nuclear or cell extract preparations), with an end-labeled DNA fragment containing the putative protein binding site. The reaction products are then analyzed on a nondenaturing polyacrylamide gel. The specificity of the DNA-binding protein for the putative binding site is established by competition experiments using DNA fragments or oligonucleotides containing a binding site for the protein of interest, or other unrelated DNA sequences.

Expression assays can be used to detect differences in expression of polymorphisms with respect to tissue specificity, expression level, or expression in response to exposure to various substrates, and/or timing of expression during development. For example, since UGT2B4 is expressed in liver, polymorphisms could be evaluated for expression in tissues
5 other than liver, or expression in liver tissue relative to a reference UGT2B4 polypeptide.

Substrate screening assay. Substrate screening assays are used to determine the metabolic activity of a UGT2B protein or peptide fragment on a substrate. Many suitable assays are known in the art, including the use of primary or cultured cells, genetically
10 modified cells (e.g., where DNA encoding the UGT2B polymorphism to be studied is introduced into the cell within an artificial construct), cell-free systems, e.g. microsomal preparations or recombinantly produced enzymes in a suitable buffer, or in animals, including human clinical trials (see, e.g., Burchell et al. (1995) Life Sci. 57:1819-1831, specifically incorporated herein by reference. Where genetically modified cells are used, since most cell
15 lines do not express UGT2B activity (liver cells lines being the exception), introduction of artificial construct for expression of the UGT2B polymorphism into many human and non-human cell lines does not require additional modification of the host to inactivate endogenous UGT2B expression/activity. Clinical trials may monitor serum, urine, etc. levels of the substrate or its metabolite(s).

20 Typically a candidate substrate is input into the assay system, and the conversion to a metabolite is measured over time. The choice of detection system is determined by the substrate and the specific assay parameters. Assays are conventionally run, and will include negative and positive controls, varying concentrations of substrate and enzyme, etc.

25 *Genotyping:* UGT2B genotyping is performed by DNA or RNA sequence and/or hybridization analysis of any convenient sample from a patient, e.g. biopsy material, blood sample (serum, plasma, etc.), buccal cell sample, etc. A nucleic acid sample from an individual is analyzed for the presence of polymorphisms in UGT2B, particularly those that affect the activity or expression of UGT2B. Specific sequences of interest include any
30 polymorphism that leads to changes in basal expression in one or more tissues, to changes in the modulation of UGT2B expression by modifiers, or alterations in UGT2B substrate specificity and/or activity.

Linkage Analysis: Diagnostic screening may be performed for polymorphisms that are genetically linked to a phenotypic variant in UGT2B activity or expression, particularly through the use of microsatellite markers or SNPs. The microsatellite marker or SNP itself may not phenotypically expressed, but is linked to sequences that result in altered activity or expression. Two polymorphic variants may be in linkage disequilibrium, *i.e.* where alleles show non-random associations between genes even though individual loci are in Hardy-Weinberg equilibrium.

Linkage analysis may be performed alone, or in combination with direct detection of phenotypically evident polymorphisms. The use of microsatellite markers for genotyping is well documented. For examples, see Mansfield *et al.* (1994) Genomics 24:225-233; and Ziegler *et al.* (1992) Genomics 14:1026-1031. The use of SNPs for genotyping is illustrated in Underhill *et al.* (1996) Proc Natl Acad Sci U S A 93:196-200.

Transgenic animals. The subject nucleic acids can be used to generate genetically modified non-human animals or site specific gene modifications in cell lines. The term "transgenic" is intended to encompass genetically modified animals having a deletion or other knock-out of UGT2B4, UGT2B7 or UGT2B15 activity, having an exogenous UGT2B4, UGT2B7 or UGT2B15 gene that is stably transmitted in the host cells, or having an exogenous UGT2B promoter operably linked to a reporter gene. Transgenic animals may be made through homologous recombination, where the UGT2B locus is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like. Of interest are transgenic mammals, *e.g.* cows, pigs, goats, horses, *etc.*, and particularly rodents, *e.g.* rats, mice, *etc.*

Genetically Modified Cells. Primary or cloned cells and cell lines are modified by the introduction of vectors comprising UGT2B4, UGT2B7 and UGT2B15 genetic polymorphisms. The gene may comprise one or more variant sequences, preferably a haplotype of commonly occurring combinations. In one embodiment of the invention, a panel of two or more genetically modified cell lines, each cell line comprising a UGT2B polymorphism, are provided for substrate and/or expression assays. The panel may further comprise cells genetically modified with other genetic sequences, including polymorphisms, particularly other sequences of interest for pharmacogenetic screening, *e.g.* UGT1, other UGT2 sequences, cytochrome oxidase polymorphisms, *etc.*

Vectors useful for introduction of the gene include plasmids and viral vectors, e.g. retroviral-based vectors, adenovirus vectors, etc. that are maintained transiently or stably in mammalian cells. A wide variety of vectors can be employed for transfection and/or integration of the gene into the genome of the cells. Alternatively, micro-injection may be employed, fusion, or the like for introduction of genes into a suitable host cell.

Genotyping Methods

The effect of a polymorphism in the UGT2B4, UGT2B7 or UGT2B15 gene sequence on the response to a particular substrate or modifier is determined by *in vitro* or *in vivo* assays. Such assays may include monitoring the metabolism of a substrate during clinical trials to determine the UGT2B enzymatic activity, specificity or expression level. Generally, *in vitro* assays are useful in determining the direct effect of a particular polymorphism, while clinical studies will also detect an enzyme phenotype that is genetically linked to a polymorphism.

The response of an individual to the substrate or modifier can then be predicted by determining the UGT2B genotype, with respect to the polymorphism. Where there is a differential distribution of a polymorphism by racial background, guidelines for drug administration can be generally tailored to a particular ethnic group.

The basal expression level in different tissue may be determined by analysis of tissue samples from individuals typed for the presence or absence of a specific polymorphism. Any convenient method may be used, e.g. ELISA, RIA, etc. for protein quantitation, northern blot or other hybridization analysis, quantitative RT-PCR, etc. for mRNA quantitation. The tissue specific expression is correlated with the genotype.

The alteration of UGT2B expression in response to a modifier is determined by administering or combining the candidate modifier with an expression system, e.g. animal, cell, *in vitro* transcription assay, etc. The effect of the modifier on UGT2B transcription and/or steady state mRNA levels is determined. As with the basal expression levels, tissue specific interactions are of interest. Correlations are made between the ability of an expression modifier to affect UGT2B activity, and the presence of the provided polymorphisms. A panel of different modifiers, cell types, etc. may be screened in order to determine the effect under a number of different conditions.

A UGT2B polymorphism that results in altered enzyme activity or specificity is determined by a variety of assays known in the art. The enzyme may be tested for metabolism of a substrate *in vitro*, for example in defined buffer, or in cell or subcellular

lysates, where the ability of a substrate to be metabolized by UGT2B4, UGT2B7 or UGT2B15 under physiologic conditions is determined. Where there are not significant issues of toxicity from the substrate or metabolite(s), *in vivo* human trials may be utilized, as previously described.

5 The genotype of an individual is determined with respect to the provided UGT2B4, UGT2B7 and UGT2B15 polymorphisms. The genotype is useful for determining the presence of a phenotypically evident polymorphism, and for determining the linkage of a polymorphism to phenotypic change.

10 A number of methods are available for analyzing nucleic acids for the presence of a specific sequence. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. The nucleic acid may be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki *et al.* (1985)
15 Science 230:1350-1354, and a review of current techniques may be found in Sambrook *et al.* Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2-14.33. Amplification may be used to determine whether a polymorphism is present, by using a primer that is specific for the polymorphism. Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, for examples see Riley *et al.* (1990) Nucleic Acids Res 18:2887-2890; and Delahunty *et al.* (1996) Am J Hum Genet
20 58:1239-1246.

 A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-
25 dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4',7'-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, e.g. ³²P, ³⁵S, ³H; etc. The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, etc. having a high affinity binding partner, e.g. avidin, specific antibodies, etc., where the binding partner
30 is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

 The sample nucleic acid, e.g. amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid may be sequenced by dideoxy or

other methods. Hybridization with the variant sequence may also be used to determine its presence, by Southern blots, dot blots, *etc.* The hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilized on a solid support, as described in U.S. 5,445,934, or in WO95/35505, may also be used as a means of detecting the presence of variant sequences. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), mismatch cleavage detection, and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease (restriction fragment length polymorphism, RFLP), the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

In one embodiment of the invention, an array of oligonucleotides are provided, where discrete positions on the array are complementary to one or more of the provided polymorphic sequences, e.g. oligonucleotides of at least 12 nt, frequently 20 nt, or larger, and including the sequence flanking the polymorphic position. Such an array may comprise a series of oligonucleotides, each of which can specifically hybridize to a different polymorphism. For examples of arrays, see Hacia *et al.* (1996) Nat Genet 14:441-447 and DeRisi *et al.* (1996) Nat Genet 14:457-460.

The genotype information is used to predict the response of the individual to a particular UGT2B substrate or modifier. Where an expression modifier inhibits UGT2B expression, then drugs that are a UGT2B substrate will be metabolized more slowly if the modifier is co-administered. Where an expression modifier induces UGT2B expression, a co-administered substrate will typically be metabolized more rapidly. Similarly, changes in UGT2B activity will affect the metabolism of an administered drug. The pharmacokinetic effect of the interaction will depend on the metabolite that is produced, e.g. a prodrug is metabolized to an active form, a drug is metabolized to an inactive form, an environmental compound is metabolized to a toxin, *etc.* Consideration is given to the route of administration, drug-drug interactions, drug dosage, *etc.*

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention,

and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperature, concentrations, etc.) but some experimental errors and deviations should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric.

EXAMPLE 1

Genotyping UGT2B4

10 Materials and Methods

DNA Samples. Blood specimens from approximately 48 individuals were collected after obtaining informed consent. All samples were stripped of personal identifiers to maintain confidentiality. The only data associated with a given blood samples was gender and self-reported major racial group designations in the United States (Caucasian, Hispanic, African American). Genomic DNA was isolated from these samples using standard techniques. DNA was stored either as a concentrated solution, or in a dried form in microtiter plates.

PCR amplifications. The primers used to amplify exons in which polymorphisms were found are shown in Table 1, and were designed with NBI's Oligo version 5.1 program.

20 Sequences for exons in which no polymorphisms were found are not shown.

Table 1. UGT2B4 PCR Primers.

Region	Primary PCR Amplification		
	Forward/ Reverse	SEQ ID NO	Sequence
UGT2B4Exon 1	F	9.	Taccttttagtgtctctttgtca
	R	10.	Ttcctggagtcttctgtatga
UGT2B4Exon 4	F	11.	Catccctgttcttctcatt
	R	12.	Cgggactggaaaataaatat
UGT2B4Exon 6	F	13.	Ggggttcaccgtgtta
	R	14.	Aaagccaagcagcactaa

25 Twenty-five nanograms of gDNA were amplified in the primary amplifications using the Perkin Elmer GeneAmp PCR kit according to the manufacturer's instructions in 25 μ l reactions with AmpliTaq Gold DNA polymerase. Reactions contained 25 mM MgCl₂ and 0.2 μ M of each primer. Thermal cycling was performed using a GeneAmp PCR System 9600

PCR machine (Perkin Elmer), utilizing a touch-down PCR protocol. The protocol, unless indicated otherwise in Table 2, consisted of an initial incubation of 95°C for 10 min, followed by ten cycles of 95°C for 20 sec, 64°C (minus 1°C per cycle) for 20 sec, 72°C for 2 min, six cycles of 95°C for 20 sec, 54°C for 20 sec, 72°C for 2 min, and nineteen cycles of 95°C for 20 sec, 54°C for 20 sec, 72°C for 2 min (plus 15 sec per cycle), and one final extension step of 72°C for 10 min.

For the secondary PCR reactions, one microliter of each primary PCR reaction was re-amplified using the primary PCR primers. The thermal cycling profile that was used for the primary PCR for an exon was also used for the secondary PCR.

Table 2.
Cycling Profile Modifications

Exon	Primary PCR	Secondary PCR
1	Touch-Down PCR step: 8 cycles	same as Primary PCR
	64° C (minus 1° C per cycle), for 15 sec	
	Total Number of cycles: 35	
4	Touch-Down PCR step: 10 cycles	same as Primary PCR
	64° C (minus 1° C per cycle), for 15 sec	
	Total Number of cycles: 35	
6	Touch-Down PCR step: 7 cycles	same as Primary PCR
	64° C (minus 1° C per cycle), for 15 sec	
	Total Number of cycles: 35	

DNA sequencing. PCR products from 48 individuals (approximately 1/3 African American, 1/3 Caucasian, 1/3 Hispanic) were prepared for sequencing by treating 8 µl of each PCR product with 0.15 µl of exonuclease I (1.5 U/reaction), 0.3 µl of Shrimp Alkaline Phosphatase (0.3U/reaction), q.s. to 10 µl with MilliQ water, and incubated at 37°C for 30 min, followed by 72°C for 15 min. Cycle sequencing was performed on the GeneAmp PCR System 9600 PCR machine (Perkin Elmer) using the ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit according to the manufacturer's directions, with the following changes: (1) 2 µl of dRhodamine terminator premix, instead of 8 µl, (2) 10% (v/v) Dimethylsulfoxide was added to each individual nucleotide. The oligonucleotide primers (unlabelled), at 3 picomoles per reaction, used for the sequencing reactions are listed in

Table 3. Sequencing reactions, with a final volume of 5 μ l, were subjected to 25 cycles at 96°C for 10 sec, 50°C for 5 sec, and 60°C for 4 min, followed by ethanol precipitation. After decanting the ethanol, samples were evaporated to dryness using a SpeedVac for roughly 15 min and were resuspended in 2 μ l of loading buffer (5:1 deionized formamide:50 mM EDTA pH 8.0), heated to 94°C for 2 min, and were electrophoresed through 5.25% polyacrylamide/6M urea gels in an ABI Prism 377 DNA Sequencer, according to the manufacturer's instructions for sequence determination. All sequences were determined from both the 5' and 3' (sense and antisense) direction.

10

Table 3. Sequencing Primers

P. No.	F/R	SEQ ID NO	Forward Primer
1	F	15.	Ccacatgctcagactgtaa
	R	16.	Caaaaataccccactaccc
2	F	17.	Ccctgttcttctcattgta
	R	18.	Ttcagtaagcttgttcatgat
3,4	F	19.	Cctggccaaattgactt
	R	20.	Caggaacccagtcacatc
5	F	21.	Ggggaaaagagattaattacg
	R	22.	Agccaagcagcactaatc
6,7	F	23.	Tccaattcacaggttacatg
	R	24.	Agccaagcagcactaatc

Table 4.
Summary of UGT2B4 polymorphisms.

Exon	Nt change	AA change	SEQ ID	Sequence
1	G 157 C	Lys 40 Asn	25.	Tggatgaatataaagacaatcctggat
			26.	Tggatgaatataaacacaatcctggat
Int.4	T 61 C		27.	Aagtgttaatagttatcatgaaacaag
			28.	Aagtgttaatagctatcatgaaacaag
6	T 1411 A	Glu 454 Asp	29.	Tgaagccccttgatcgagcagcttct
			30.	Tgaagccccttgaacgagcagcttct
6	C 1412 A		31.	Tgaagccccttgatcgagcagcttct
			32.	Tgaagccccttgatagagcagcttct
6	T 1849 C		33.	Gatataaagccatacgagggtatattg
			34.	Gatataaagccatatgagggtatattg
6	A 1919 C		35.	Cagggtacatgaaaaaaaaatttacta
			36.	Cagggtacatgaaaaacaatttacta
6	A 2072 G		37.	Tgttgaggaagctaataaataattaa
			38.	Tgttgaggaaactaataaataattaa

5 Nucleotide variants in exons are numbered from first base in Sequence 1. Amino Acid changes are numbered beginning with the first methionine in the protein sequence provided in Sequence 1. The nucleotide variant in intron 4 is numbered from the beginning of intron 4, as provided in Sequence 2.4.

EXAMPLE 2

UGT2B7 Genotyping

10 Twenty-five nanograms of gDNA were amplified in the primary amplifications using the Perkin Elmer GeneAmp PCR kit according to the manufacturer's instructions in 25 μ l reactions with AmpliTaq Gold DNA polymerase. Reactions contained 25 mM MgCl₂ and 0.2 μ M of each primer. Thermal cycling was performed using a GeneAmp PCR System 9600
 15 PCR machine (Perkin Elmer), utilizing a touch-down PCR protocol. The exons for UGT2B7 were amplified using the following cycling conditions: An initial incubation at 96°C for 10 min., followed by 16 cycles of 95°C for 20 sec., 52°C for 20 sec., 72°C for 2 min., and nineteen cycles of 95°C for 20 sec, 52°C for 20 sec, 72°C for 2 min (plus 15 sec per cycle), and one final extension step of 72°C for 10 min.

For the secondary PCR reactions, one microliter of each primary PCR reaction was re-amplified using the primary PCR primers. The thermal cycling profile that was used for the primary PCR for an exon was also used for the secondary PCR.

The amplification primers are provided in Table 5, the sequencing primers in Table 5
6, and the polymorphisms in Table 7.

Table 5
PCR Primers for UGT2B7 Amplification

Region		SEQ ID NO	Primer Sequence
UGT2B7 Exon 1	Primary F	46.	Cttggctaatttatcttgg
	Primary R	47.	Cccactaccctgactttat
	Secondary F	48.	Ggacataaccatgagaaatg
	Secondary R	49.	Agctctgctcaaagacac
UGT2B7 Exon 2	Primary F	50.	Tgtccgatgctactattgaa
	Primary R	51.	Tgtgtaaatcccttgtaaat
	Secondary F	52.	Ttttttttctattcctgtcag
	Secondary R	53.	Ctttaccaccaccattt
UGT2B7 Exon 4	Primary F	54.	Cccttgatctcattcctact
	Primary R	55.	Aactggctattcttagatgtatg
	Secondary F	56.	Cattcctactctttatacagttctc
	Secondary R	57.	Cccccgattcagactat
UGT2B7 Exon 5	Primary F	58.	Cccttgatctcattcctact
	Primary R	59.	Aactggctattcttagatgtatg
	Secondary F	60.	Tcctccgaagtctgaaac
	Secondary R	61.	Tataaaaaggatgaaactcacac
UGT2B7 Exon 6	Primary F	62.	Caagccccaagttatgt
	Primary R	63.	Cagtaggatccgcatataa
	Secondary F	64.	Tctgaggggtttgtctgta
	Secondary R	65.	Ccgcatataagttcaacaa

10 *DNA sequencing.* PCR products from 48 individuals were prepared for sequencing by treating 8 μ L of each PCR product with 0.15 μ L of exonuclease I (1.5U/reaction), 0.3 μ L of Shrimp Alkaline Phosphatase (0.3U/reaction), q.s. to 10 μ L with MilliQ water, and incubated at 37°C for 30 min, followed by 72°C for 15 min. Cycle sequencing was performed

on the GeneAmp PCR System 9600 PCR machine (Perkin Elmer) using the ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit or the ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit according to the manufacturer's directions, with the following changes: For the ABI Prism dRhodamine Terminator kit, (1) 2 μ L of
5 dRhodamine terminator premix, instead of 8 μ L, (2) 10% (v/v) Dimethylsulfoxide was added to each individual nucleotide, (3) 5 μ L total volume instead of 20 μ L. For the ABI Prism Big Dye Terminator kit (1) 0.8 μ L of Big Dye terminator premix, instead of 8 μ L, and (2) 15 μ L total volume instead of 20 μ L. The oligonucleotide primers (unlabeled), at 3 picomoles per reaction, used for the sequencing reactions are listed in Table 6. Sequencing reactions, with
10 a final volume of 5 μ L, were subjected to 25 cycles at 96°C for 10 sec, 50°C for 5 sec, and 60°C for 4 min, followed by ethanol precipitation. After decanting the ethanol, samples were evaporated to dryness using a SpeedVac for roughly 15 min and were resuspended in 2 μ L of loading buffer (5:1 deionized formamide:50 mM EDTA pH 8.0), heated to 94°C for 2 min, and were electrophoresed through 5.25% polyacrylamide/6M urea gels in an ABI Prism 377
15 DNA Sequencer, according to the manufacturer's instructions for sequence determination. All sequences were determined from both the 5' and 3' (sense and antisense) direction.

Table 6
Sequencing Primers UGT2B7

P. No.	F/R	SEQ ID NO	Primer Sequence
1, 2	F	66.	Ggacataacctagagaaatg
	R	67.	Ttaagagcggatgagttgt
3, 4	F	68.	Tcatcatgcaacagattaag
	R	69.	Cactacagggaataatagca
5	F	70.	Acccttggtacagtctca
	R	71.	Agctctgctcaaagacac
6, 7	F	72.	Ttgctacattattctaacc
	R	73.	Cttacccacccattt
8, 9	F	74.	Cattctactctttatacagttctc
	R	75.	Ccccgattcagactat
10	F	76.	Cattctactctttatacagttctc
	R	77.	Ccccgattcagactat
11, 12	F	78.	Tcctccgaagtctgaaac
	R	79.	Tataaaaaggatgaaactcacac
13	F	80.	Tctgaggggtttgtctgta
	R	81.	Tttttgtctcaggaagaaaga
14	F	82.	Aaaaaagaaaaaaaaatcttttc
	R	83.	Ccgcatataagttcaacaa

Table 7
Summary of Sequence Polymorphisms UGT2B7

N	Exon	Nt change	AA change	SEQ ID NO.	Sequence
1	1	G 13 A		84.	Tgcattgcaccaggatgtctgt
				85.	Tgcattgcaccaagatgtctgt
2	1	T 151 C	Leu 107 Phe	86.	Tcctggatgagcttattcagaga
				87.	Tcctggatgagcctattcagaga
3	1	A 236 T		88.	Cattttggttatattttcac
				89.	Cattttggtttattttcac
4	1	A 286 G		90.	Cataactagaaagttctgtaa
				91.	Cataactaggaagttctgtaa
5	1	C 450 T	Thr 179 Ile	92.	Cctggctacactttgaaaa
				93.	Cctggctacattttgaaaa
6	2	A 14 G		94.	Gaagaccactacattatctg
				95.	Gaagaccactacgttatctg
7	2	AT 80-81 TC		96.	Aatttcagttccatatccactctt
				97.	Aatttcagttcctcatccactctt
8	4	C 57 G		98.	Taggtctcaatactcggtcta
				99.	Taggtctcaatactcggtcta
9	4	C 60 T		100.	Tacaagtggataccccaga
				101.	Tataagtggataccccaga
10	In.4	A 154 del		102.	Gggagaaagaatacattataatttt
				103.	Gggagaaagaataactataatttt
11	5	C 101 T		104.	Ttccattgttgccgatcaac
				105.	Ttccattgttgctgatcaac
12	5	A 198 C	Lys 430 Gln	106.	Gaatgcattgaagagagtaat
				107.	Gaatgcattgcagagagtaat
13	6	A 197 G		108.	Ctggctctgtgtggcaactgtga
				109.	Ctggctctgtgtggcgactgtga
14	6	C 528 A		110.	Taagataaagccttatgag
				111.	Taagataaagacttatgag

Example 3
Genotyping UGT2B15

Sequencing and analysis were performed as described in Example 2. The amplification primers are provided in Table 9, the sequencing primers in Table 8, and the polymorphisms in Table 10.

Table 8
Sequencing Primers UGT2B15

Region		SEQ ID NO	Primer Sequence
UGT2B15 Exon 1	Primary F	119.	catgcacctattcagactgt
	Primary R	120.	tgggtgtcctgtagtagta
	Secondary F	121.	attgattttcctcagataaagta
	Secondary R	122.	tcataattcccttaaaaacac
UGT2B15 Exon 2	Primary F	123.	atatgtttgggtatgtattcc
	Primary R	124.	ccatattcccctcactct
	Secondary F	125.	atacctgcatattcaataacaa
	Secondary R	126.	tatccagccattccttct
UGT2B15 Exon 5	Primary F	127.	agttttgtgggtataatgttac
	Primary R	128.	aaacgggttaaaattcata
	Secondary F	129.	tcataccttgtaattaataatttg
	Secondary R	130.	cgggttaaaattcatattca
UGT2B15 Exon 6	Primary F	131.	tcatgccaattcagtgac
	Primary R	132.	accctccatgctgaat
	Secondary F	133.	tcaaagaccatccatagactt
	Secondary R	134.	ggagtcccattcttcagtc

Table 9
PCR Primers UGT2B15

P. No.	F/R	SEQ ID NO	Primer Sequence
1,2	F	135.	Attgattttcctcagatataagta
	R	136.	Attactggcattgacaag
3	F	137.	Attgattttcctcagatataagta
	R	138.	Tgtacagaaagggtatgttaa
4	F	139.	aaaaat g/t atttgaagattc
	R	140.	Tcataatttccttaaaaacac
5	F	141.	Atacctgcatattcaaataacaa
	R	142.	Tatccagccattccttct
6,7	F	143.	Tcataccttgtaattaataatttg
	R	144.	Cgggttaaaattcatattca
8,9	F	145.	Tcaaagaccatccatagactt
	R	146.	Ggagtcctcatcttcagtc

Table 10
Summary of Sequence Polymorphisms UGT2B15

N	Exon	Ntd change	AA change	SEQ ID NO.	Sequence
1	1	A 53 G	Ser 15 Gly	147.	tgatacagctcagttgttac
				148.	tgatacagctcggttgttac
2	1	T 184 G		149.	tgttgacatcttcggcttct
				150.	tgttgacatcgctggcttct
3	1	G 263 T	Asp 85 Tyr	151.	ctttaactaaaaatgatttgga
				152.	ctttaactaaaaattatttgga
4	1	T 519 C	Leu 170 Pro	153.	tttaacatacccttcgtaca
				154.	tttaacatacccttcgtaca
5	2	C 122 G	His 282 Gln	155.	tggaggacttcactgtaaacc
				156.	tggaggacttcagtgtaaacc
6	5	G 59 A		157.	tatgaggcgatctaccatgggat
				158.	tatgaggcaatctaccatgggat
7	5	C 100 T	Ala 398 Val	159.	cccttgttgctggatcaacatgat
				160.	cccttgttgtggatcaacatgat
8	6	G 14 A	Val 443 Ile	161.	aaagagaatgtcatgaaattat
				162.	aaagagaatatcatgaaattat
9	6	C 523 A	Thr 523 Lys	163.	gcttgccaaaaacaggaaagaa
				164.	gcttgccaaaaaaggaaagaa

5 All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

10 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

What is Claimed is:

1. An isolated nucleic acid molecule comprising a UGT2B sequence polymorphism of SEQ ID NOs:25-38; 84-111 or 147-164, as part of other than a naturally occurring chromosome.
- 5 2. A nucleic acid probe for detection of UGT2B locus polymorphisms, comprising a polymorphic sequence of SEQ ID NOs:25-38; 84-111 or 147-164.
3. A nucleic acid probe according to Claim 2, wherein said probe is conjugated
10 to a detectable marker.
4. An array of oligonucleotides comprising:
two or more probes for detection of UGT2B locus polymorphisms, said probes comprising at least one form of a polymorphic sequences of SEQ ID NOs:25-38; 84-111 or
15 147-164.
5. A method for detecting in an individual a polymorphism in a UGT2B metabolism of a substrate, the method comprising:
analyzing the genome of said individual for the presence of at least one UGT2B
20 polymorphism of SEQ ID NOs:25-38; 84-111 or 147-164; wherein the presence of said predisposing polymorphism is indicative of an alteration in UGT2B expression or activity.
6. A method according to Claim 5, wherein said analyzing step comprises detection of specific binding between the genomic DNA of said individual with an array of
25 oligonucleotides comprising:
two or more probes for detection of UGT2B locus polymorphisms, said probes comprising at least one form of a polymorphic sequence of SEQ ID NOs:25-38; 84-111 or 147-164.
- 30 7. A method according to Claim 5, wherein said alteration in UGT2B expression is tissue specific.
8. A method according to Claim 5, wherein said alteration in UGT2B expression is in response to a UGT2B modifier.

9. A method according to Claim 8, wherein said modifier induces UGT2B expression.

5 10. A method according to Claim 8, wherein said modifier inhibits UGT2B expression.

SEQUENCE LISTING

<110> Penny, Laura
Galvin, Margaret
Miller, Andrew
Reidy, Michael

<120> Genotyping Human
UDP-Glucuronosyltransferase 2B4 (UGT2B4), 2B7 (UGT2B7) and
2B15 (UGT2B15) Genes

<130> SEQ-22PRV2

<160> 164

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 1323
<212> DNA
<213> H. sapiens

<220>
<221> Other
<222> (140)... (897)

<400> 1
tcactctacct tttagttgtc tctttgtcat ccacatgctc agactgttaa tataatgtat 60
ttacttttgaa gtgtaaaagt tacatttta cttcttgact gatttatact ggatgtcacc 120
atgagaaatg acagaaagga gcagcaactg gaaaacaagc attgcattgc atcaggatgt 180
ctatgaaatg gacttcagct cttctgctga tacagctgag ctgttacttt agctctggga 240
gttggtgaaa ggtgctgggt tggccacag aattcagcca ctggatgaat ataaagacaa 300
tcctggatga acttgtccag agaggtcatg aggtgactgt attggcatct tcagcttcca 360
tttctttcga tcccaacagc ccatctactc ttaaatttga agtttatcct gtatctttaa 420
ctaaaactga gtttgaggat attatcaagc agctgggttaa gagatgggca gaacttccaa 480
aagacacatt ttggtcatat ttttcacaag tacaagaaat catgtggaca tttaatgaca 540
tacttagaaa gttctgtaag gatatagttt caaataagaa acttatgaag aaactacagg 600
agtcaagatt tgatgttggt cttgcagatg ctgttttccc ctttggtgag ctgctggccg 660
agttacttaa aatacccttt gtctacagcc tccgcttctc tcctggctac gcaattgaaa 720
agcatagtgg aggacttctg ttccctcctt cctatgtgcc tgttggtatg tcagaactaa 780
gtgaccaaat gactttcata gagagggtaa aaaatatgat ctatgtgctt tttttgaa 840
tttggttcca aatatttgac atgaagaagt gggatcagtt ctacagtga gttctaggta 900
agtaactttt ttgattggta acatgaagat ctaactttct tgtaccttg aagctgagtt 960
tgtataaagc cataaagtca gggtagtggg gtatttttgt aatgaattta tcaaatgaaa 1020
ttgtaagatg atctacaaaa ctcacaagca ctatagaaaa tgtaaattat aggatcagtt 1080
aaaactctgt ggccatcact catacagaag actccaggaa gtcataagcc tgtatattag 1140
tgacacctaa atttctttaa gcaatcacat atctgtttta ttatacattt tttcatctta 1200
aaaaaaagtc agacttattc agaaacatct tgctgaatgc atactggtag attgagtagt 1260
tacacatttt ttagaactat ctatataaca ttgcagaaat tgttttttct tgtatatttg 1320
cag 1323

<210> 2
<211> 746
<212> DNA
<213> H. sapiens

<220>

<221> Other

<222> (195)... (344)

<400> 2

ttcttgtaaa	tacacatggg	taaaatatat	aatacataaa	aattaaatta	tgcctatata	60
cgaatatatg	tatttttttt	caaggcacaa	acactttgcc	tacatttttg	cccacattat	120
tctaacttct	ttcagaaaat	tacctagtgt	aattatcttg	tgcatctat	cttttctttt	180
ttttccccc	atcaggaaga	cccactacgt	tatctgagac	aatggcaaaa	gctgacatat	240
ggcttattcg	aaactactgg	gattttcaat	ttcctcacc	actcttacca	aatggttgagt	300
tcgttgagg	actccactgc	aaacctgcc	aacctctacc	gaaggtaa	tattactgtt	360
tggtttgtct	gctttgaagt	ttcagtacga	atggttctat	attcattcaa	agtgtttgac	420
ttacactgga	agaaaggtgg	aagtgggaag	agtaaagcag	ataccaatta	gaaactgacg	480
tacatgttga	tactatcaca	agtttatgaa	tttcatcatt	attaccaata	aagagggata	540
ctaaagagac	tttgaaaata	gggttggtaa	attaaagctt	tgattatgca	acataataag	600
aggtactggc	cattcattca	aagaatattt	ataaagagat	tagcacacac	cacaggtacg	660
tgtatgggac	acagtttcta	tccaacaca	ccttacattc	tattttgaaa	gatagaatat	720
atgcaagtaa	taaaaactgt	gtaaaa				746

<210> 3

<211> 785

<212> DNA

<213> H. sapiens

<220>

<221> Other

<222> (238)... (369)

<400> 3

ttcacaaacg	cacacacata	cacacacaca	tatttacaca	aagaccctta	acagaggcaa	60
cctatctcat	attatacata	ttgcaaaaaa	aactgagtaa	ttgagtcagt	taaaaaacat	120
cctttactcc	aataattcct	gataaaactt	gattttctct	ctttttataa	caattctttc	180
acagtgcctg	ctgtgctgat	aatctattat	gatagaacaa	attctttttt	ttcacaggaa	240
atggaagagt	ttgtccagag	ctctggagaa	aatggtgttg	tggtgttttc	tctggggctg	300
atggtcagta	acacgtcaga	agaaagggcc	aatgtaattg	catcagccct	tgccaagatc	360
ccacaaaagg	taagataaaa	tggttttaag	gtgtaaaaaa	ctactgaaag	aggctgttaa	420
agtttgtaaa	gaacccaatt	gtagaaactt	cctgcctata	tattcagctg	ttgggaaagc	480
actaattatc	tcagatatata	attcaaaatc	aaaaatatgt	atggaagatg	ataaaactcat	540
acagaagggtg	tttttcattg	gtaatttaatt	tggcattaat	attgtgatca	ggaataaata	600
caattaagag	ttgcaggtaa	agtttttgta	ttatcatgat	actggggcta	ggtaagagct	660
atcaccaaat	tctgccctg	tgatttgatc	cttttgttta	agaactcctg	agggcgatgt	720
acatcctaca	ggtgttagaa	aacgttacat	tttaatgagt	aacttcacta	gcacaataac	780
aatag						785

<210> 4

<211> 1138

<212> DNA

<213> H. sapiens

<220>

<221> Other

<222> (395)... (482)

<400> 4

catctgttat	tttttgagtt	tttaataatg	gccattctga	ctggtgtgag	atggtatctc	60
tttgtggatt	taaccagtga	tgtaaacctt	tttttcatat	agtggtttgc	cacatatagt	120
tttcttttga	aaagtgtaac	aactttttta	atacttgaa	ttttcattga	ttatcttatt	180
tgtctaagct	actattttga	aaaatcatga	tttccttata	tacctaatta	tgaaattaag	240
gaaatgaaat	atgagtattc	tatttacatc	agtcgtgagta	gttcttggtta	cttaacatcc	300
cttggtcttc	tcattgttaa	tctctttaga	tttctaacat	tctatgactt	ttgagttcca	360
ctcatgggat	aagatatttt	cttcactgta	acaggttctg	tggagatttg	atgggaataa	420
accagatact	ttaggactca	atactcggct	gtacaagtgg	ataccccgag	atgatcttct	480
tggttaagtct	ctgaagaaca	aatactgaat	atattagtaa	cagattatta	aagtgttaat	540

WO 00/06776

agctatcatg	aaacaagctt	actgaacatt	tgttatggaa	aaacttaaaa	ataaaatgaa	600
acttctttat	atttattttc	cagtcccggg	ggaaaagaat	aaattggttg	cattttatga	660
tatgcaccca	cattctttac	aatcagagtc	agagtatctt	tatttcagggt	gttattacct	720
cccacagaat	ttttctggca	cttcctgggt	tgtcttcctt	tctcatattt	ctacaacttt	780
acacctgttc	tttctcctc	tgtaggggta	tttcaaatgt	cactaaaagt	aacagctctt	840
ctgctatcac	cagggatgct	gcattttctg	taggattaaa	tccctaattct	taatcaaaaa	900
gtgatgacac	atttcataat	gaaatgtgac	ctgtctttcc	tcaattctag	caccaccacc	960
acctcactgc	ctgctgcctt	gcacacccta	catatccaac	tccgtgactg	tacttaagag	1020
aacacattct	ggctgggcac	ggtgctcacg	cctgcaatcc	tagcactttg	ggaggctgat	1080
ggcaggtgga	ttgactgagc	tcaggaggttc	aagaccatcc	tgggcaacat	ggtgaaac	1138

<210> 5
 <211> 689
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (123)... (342)

<400> 5						60
aaaaacaatt	ttaattcagt	tcagtgtggt	atctaggaaa	caccgtcaca	ttcagattct	120
tccattgtgc	atttctcatt	ttattcctat	gaataatttt	gctaaaattc	atccaatcct	180
aggtcaccca	aaaaccagag	cttttataac	tcatggtgga	gccaatggca	tctatgaggc	240
aatctaccat	ggaatcccta	tggtagggcg	tccattgttt	gcagatcaac	ctgataacat	300
tgcacacatg	aaggccaagg	gagcagctgt	tagtttgac	ttccacacaa	tgctgagtag	360
agacttactc	aatgcactga	agacagtaat	taatgatcct	ttgtgagtag	aactttttt	420
ttactcgggtg	gtctttatag	atagggtccc	ttgtgaatag	tgagtatgac	ttttatcctt	480
tttataagcg	actgatttcg	aaagaattta	agtgtattta	acaatctgaa	atctgctttt	540
atttttgagt	ggttatttta	aaattttatt	tgaaccacat	acatttaatg	aataatcaat	600
tattgaaata	attttctaca	caaaaataat	tttaaagtga	tatagataag	aagacatttt	660
aaaaataatt	tgacgtaatc	aatccacagt	agaaaggaaa	gataaacttg	acgtaatata	689
ataaaatatt	ttaattcaat	atctaaaat				

<210> 6
 <211> 1589
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (731)... (1475)

<400> 6						60
atgcttaagc	aatgggtagc	ctttcttcat	gatgtgatta	tttcacactg	cagcctgtat	120
caaaacatct	catgcacctc	atagaaaaat	accctacta	tgtaaccaca	aaaactaaaa	180
attaaaagaa	aataaaattg	ctcatatgtt	ctctgcctca	aataattaac	tttctcacct	240
gacctccat	ttttacttta	aaaatatttg	tcaattatga	aattccaatt	taaaagccaa	300
actttctatg	atgactcaaa	ttaaaataca	cacattctat	gtcaattcta	tgacatttac	360
tttgaatgat	ctggcacttt	aaaaaccttt	cgtggacttg	atgtgctcag	gcaaattaac	420
ttaccttctc	tttttttgag	aggggaagtct	cactctgtca	ccaggctgga	gtgcagtggg	480
gtgattgtgg	ctcactgcaa	cttcgcctc	ttgggttcaa	gcgattctcc	tgccctcagcc	540
tctcaagtag	ctgggactac	aggcacatgc	caccacgcct	gggtaatctt	ttttttttt	600
ttttttttca	tatttttact	ggagacgggg	tgaacggggg	tcggaaagtg	ctgggattgc	660
gggtcttgatc	tcctgacctc	gtgatccgcc	cgccctgacc	aatgttgata	cttttctgct	720
agggtgtgagc	ctccgtgcct	ggccaaattg	acttactttc	aattcatcat	gatcaaccag	780
tatcgtttag	atataaagag	aatgctatga	aattatcaag	aatgctatcat	aaaggagcca	840
tgaagcccct	tgatcgagca	gtcttctgga	ttgaatttgt	catgcgccat	ttggatgtga	900
agcaccttcg	ggttgcagcc	cacgacctca	cctgggtcca	gtaccactct	tgtctgtttt	960
ctgggttcct	gctggcctgt	gtggcaactg	tgatattcat	catcacaaaa	cgtctgaggc	1020
gtgtctggaa	gtttgttaga	acaggaaaga	aggggaaaag	agattaatta	agacggtgtg	1080
tggaaagctgg	gaaacccaat	aaatgaactc	ctttagttta	ttacaacaag		

PCT/US99/16675

```
<210> 7
<211> 2092
<212> DNA
<213> H. sapiens
```

```
<220>
<221> CDS
<222> (38)...(1621)
```

<400> 7																	
agcagc	aact	ggaaa	acaag	cattg	cattg	catc	cagg	atg	tct	atg	aaa	tgg	act			55	
								Met	Ser	Met	Lys	Trp	Thr				
								1				5					
tca	gct	ctt	ctg	ctg	ata	cag	ctg	agc	tgt	tac	ttt	agc	tct	ggg	agt	103	
Ser	Ala	Leu	Leu	Leu	Ile	Gln	Leu	Ser	Cys	Tyr	Phe	Ser	Ser	Gly	Ser		
			10					15					20				
tgt	gga	aag	gtg	ctg	gtg	tgg	ccc	aca	gaa	ttc	agc	cac	tgg	atg	aat	151	
Cys	Gly	Lys	Val	Leu	Val	Trp	Pro	Thr	Glu	Phe	Ser	His	Trp	Met	Asn		
		25					30					35					
ata	aag	aca	atc	ctg	gat	gaa	ctt	gtc	cag	aga	ggg	cat	gag	gtg	act	199	
Ile	Lys	Thr	Ile	Leu	Asp	Glu	Leu	Val	Gln	Arg	Gly	His	Glu	Val	Thr		
	40					45					50						
gta	ttg	gca	tct	tca	gct	tcc	att	tct	ttc	gat	ccc	aac	agc	cca	tct	247	
Val	Leu	Ala	Ser	Ser	Ala	Ser	Ile	Ser	Phe	Asp	Pro	Asn	Ser	Pro	Ser		
55					60					65					70		
act	ctt	aaa	ttt	gaa	gtt	tat	cct	gta	tct	tta	act	aaa	act	gag	ttt	295	
Thr	Leu	Lys	Phe	Glu	Val	Tyr	Pro	Val	Ser	Leu	Thr	Lys	Thr	Glu	Phe		
				75					80					85			
gag	gat	att	atc	aag	cag	ctg	gtt	aag	aga	tgg	gca	gaa	ctt	cca	aaa	343	
Glu	Asp	Ile	Ile	Lys	Gln	Leu	Val	Lys	Arg	Trp	Ala	Glu	Leu	Pro	Lys		
			90					95					100				
gac	aca	ttt	tgg	tca	tat	ttt	tca	caa	gta	caa	gaa	atc	atg	tgg	aca	391	
Asp	Thr	Phe	Trp	Ser	Tyr	Phe	Ser	Gln	Val	Gln	Glu	Ile	Met	Trp	Thr		
		105				110						115					
ttt	aat	gac	ata	ctt	aga	aag	ttc	tgt	aag	gat	ata	gtt	tca	aat	aag	439	
Phe	Asn	Asp	Ile	Leu	Arg	Lys	Phe	Cys	Lys	Asp	Ile	Val	Ser	Asn	Lys		
	120					125					130						
aaa	ctt	atg	aag	aaa	cta	cag	gag	tca	aga	ttt	gat	gtt	gtt	ctt	gca	487	
Lys	Leu	Met	Lys	Lys	Leu	Gln	Glu	Ser	Arg	Phe	Asp	Val	Val	Leu	Ala		
135					140					145					150		
gat	gct	gtt	ttc	ccc	ttt	ggg	gag	ctg	ctg	gcc	gag	tta	ctt	aaa	ata	535	
Asp	Ala	Val	Phe	Pro	Phe	Gly	Glu	Leu	Leu	Ala	Glu	Leu	Leu	Lys	Ile		

PCT/US99/16675

-5-

aag gcc aag gga gca gct gtt agt ttg gac ttc cac aca atg tcg agt 1303
 Lys Ala Lys Gly Ala Ala Val Ser Leu Asp Phe His Thr Met Ser Ser
 410 415 420
 aca gac tta ctc aat gca ctg aag aca gta att aat gat cct tta tat 1351
 Thr Asp Leu Leu Asn Ala Leu Lys Thr Val Ile Asn Asp Pro Leu Tyr
 425 430 435
 aaa gag aat gct atg aaa tta tca aga att cat cat gat caa cca gtg 1399
 Lys Glu Asn Ala Met Lys Leu Ser Arg Ile His His Asp Gln Pro Val
 440 445 450
 aag ccc ctt gat cga gca gtc ttc tgg att gaa ttt gtc atg cgc cat 1447
 Lys Pro Leu Asp Arg Ala Val Phe Trp Ile Glu Phe Val Met Arg His
 455 460 465 470
 aaa gga gcc aag cac ctt cgg gtt gca gcc cac gac ctc acc tgg ttc 1495
 Lys Gly Ala Lys His Leu Arg Val Ala Ala His Asp Leu Thr Trp Phe
 475 480 485
 cag tac cac tct ttg gat gtg act ggg ttc ctg ctg gcc tgt gtg gca 1543
 Gln Tyr His Ser Leu Asp Val Thr Gly Phe Leu Leu Ala Cys Val Ala
 490 495 500
 act gtg ata ttc atc atc aca aaa tgt ctg ttt tgt gtc tgg aag ttt 1591
 Thr Val Ile Phe Ile Ile Thr Lys Cys Leu Phe Cys Val Trp Lys Phe
 505 510 515
 gtt aga aca gga aag aag ggg aaa aga gat taattacgtc tgaggctgga 1641
 Val Arg Thr Gly Lys Lys Gly Lys Arg Asp
 520 525
 agctgggaaa cccaataaat gaactccttt agtttattac aacaagaaga cgttgtgata 1701
 caagagattc ctttcttctt gtgacaaaac atctttcaaa acttaccttg tcaagtcaaa 1761
 atttggttta gtacctgttt aaccattaga aatatttcat gtcaaggagg aaaacattag 1821
 ggaaacaaaa aatgatataa agccatacga ggttatattg aaatgtattg agcttatatt 1881
 gaaattttatt gttccaattc acagggttaca tgaaaaaaa tttactaagc ttaactacat 1941
 gtcacacatt gtacatggaa acaagaacat taagaagtcc actgacagta tcagtactgt 2001
 tttgcaaata ctacagcatac tttggatcca tttcatgcag gattgtgttg ttttaactgt 2061
 tgttgaggaa actaataaat aattaaattg t 2092

<210> 8

<211> 528

<212> PRT

<213> H. sapiens

<400> 8

Met Ser Met Lys Trp Thr Ser Ala Leu Leu Leu Ile Gln Leu Ser Cys
 1 5 10 15
 Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp Pro Thr Glu
 20 25 30
 Phe Ser His Trp Met Asn Ile Lys Thr Ile Leu Asp Glu Leu Val Gln
 35 40 45
 Arg Gly His Glu Val Thr Val Leu Ala Ser Ser Ala Ser Ile Ser Phe
 50 55 60
 Asp Pro Asn Ser Pro Ser Thr Leu Lys Phe Glu Val Tyr Pro Val Ser
 65 70 75 80
 Leu Thr Lys Thr Glu Phe Glu Asp Ile Ile Lys Gln Leu Val Lys Arg
 85 90 95
 Trp Ala Glu Leu Pro Lys Asp Thr Phe Trp Ser Tyr Phe Ser Gln Val
 100 105 110
 Gln Glu Ile Met Trp Thr Phe Asn Asp Ile Leu Arg Lys Phe Cys Lys

```

      115      120      125
Asp Ile Val Ser Asn Lys Lys Leu Met Lys Lys Leu Gln Glu Ser Arg
      130      135      140
Phe Asp Val Val Leu Ala Asp Ala Val Phe Pro Phe Gly Glu Leu Leu
145      150      155      160
Ala Glu Leu Leu Lys Ile Pro Phe Val Tyr Ser Leu Arg Phe Ser Pro
      165      170      175
Gly Tyr Ala Ile Glu Lys His Ser Gly Gly Leu Leu Phe Pro Pro Ser
      180      185      190
Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln Met Thr Phe Ile
      195      200      205
Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr Phe Glu Phe Trp Phe
210      215      220
Gln Ile Phe Asp Met Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val Leu
225      230      235      240
Gly Arg Pro Thr Thr Leu Ser Glu Thr Met Ala Lys Ala Asp Ile Trp
      245      250      255
Leu Ile Arg Asn Tyr Trp Asp Phe Gln Phe Pro His Pro Leu Leu Pro
      260      265      270
Asn Val Glu Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro Leu
275      280      285
Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly Val
290      295      300
Val Val Phe Ser Leu Gly Ser Met Val Ser Asn Thr Ser Glu Glu Arg
305      310      315      320
Ala Asn Val Ile Ala Ser Ala Leu Ala Lys Ile Pro Gln Lys Val Leu
      325      330      335
Trp Arg Phe Asp Gly Asn Lys Pro Asp Thr Leu Gly Leu Asn Thr Arg
      340      345      350
Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr
      355      360      365
Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile Tyr Glu Ala Ile
370      375      380
Tyr His Gly Ile Pro Met Val Gly Val Pro Leu Phe Ala Asp Gln Pro
385      390      395      400
Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Val Ser Leu Asp
      405      410      415
Phe His Thr Met Ser Ser Thr Asp Leu Leu Asn Ala Leu Lys Thr Val
      420      425      430
Ile Asn Asp Pro Leu Tyr Lys Glu Asn Ala Met Lys Leu Ser Arg Ile
      435      440      445
His His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile
450      455      460
Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala Ala
465      470      475      480
His Asp Leu Thr Trp Phe Gln Tyr His Ser Leu Asp Val Thr Gly Phe
      485      490      495
Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile Thr Lys Cys Leu
500      505      510
Phe Cys Val Trp Lys Phe Val Arg Thr Gly Lys Lys Gly Lys Arg Asp
515      520      525

```

<210> 9
 <211> 24
 <212> DNA
 <213> H. sapiens

<400> 9
 taccttttag ttgtctcttt gtca

24

<210> 10
 <211> 21

<212> DNA	
<213> H. sapiens	
<400> 10	21
ttcctggagt cttctgtatg a	
<210> 11	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 11	20
catcccttgt tcttctcatt	
<210> 12	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 12	20
cgggactgga aaataaatat	
<210> 13	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 13	17
ggggtttcac cgtgtta	
<210> 14	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 14	18
aaagccaagc agcactaa	
<210> 15	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 15	20
ccacatgctc agactgttaa	
<210> 16	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 16	19
caaaaatacc ccactaccc	
<210> 17	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 17	21
cccttgttct tctcattgtt a	

<210> 18	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 18	
ttcagtaagc ttgtttcatg at	22
<210> 19	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 19	
cctggccaaa ttgactt	17
<210> 20	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 20	
caggaaccaca gtcacatc	18
<210> 21	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 21	
ggggaaaaga gattaattac g	21
<210> 22	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 22	
agccaagcag cactaatc	18
<210> 23	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 23	
tccaattcac aggttacatg	20
<210> 24	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 24	
agccaagcag cactaatc	18
<210> 25	
<211> 27	
<212> DNA	
<213> H. sapiens	
<400> 25	

tggatgaata taaagacaat cctggat 27
 <210> 26
 <211> 27
 <212> DNA
 <213> H. sapiens
 <400> 26
tggatgaata taaacacaat cctggat 27
 <210> 27
 <211> 27
 <212> DNA
 <213> H. sapiens
 <400> 27
aagtgttaat agttatcatg aaacaag 27
 <210> 28
 <211> 27
 <212> DNA
 <213> H. sapiens
 <400> 28
aagtgttaat agctatcatg aaacaag 27
 <210> 29
 <211> 27
 <212> DNA
 <213> H. sapiens
 <400> 29
tgaagcccct tgatcgagca gtcttct 27
 <210> 30
 <211> 27
 <212> DNA
 <213> H. sapiens
 <400> 30
tgaagcccct tgaacgagca gtcttct 27
 <210> 31
 <211> 27
 <212> DNA
 <213> H. sapiens
 <400> 31
tgaagcccct tgatcgagca gtcttct 27
 <210> 32
 <211> 27
 <212> DNA
 <213> H. sapiens
 <400> 32
tgaagcccct tgatagagca gtcttct 27
 <210> 33
 <211> 27
 <212> DNA
 <213> H. sapiens

<400> 33
 gatataaagc catacgaggt tatattg 27
 <210> 34
 <211> 27
 <212> DNA
 <213> H. sapiens

<400> 34
 gatataaagc catatgaggt tatattg 27
 <210> 35
 <211> 26
 <212> DNA
 <213> H. sapiens

<400> 35
 caggttacat gaaaaaaaaat ttacta 26
 <210> 36
 <211> 26
 <212> DNA
 <213> H. sapiens

<400> 36
 caggttacat gaaaaacaat ttacta 26
 <210> 37
 <211> 27
 <212> DNA
 <213> H. sapiens

<400> 37
 ttgttgagga agctaataaa taattaa 27
 <210> 38
 <211> 27
 <212> DNA
 <213> H. sapiens

<400> 38
 ttgttgagga aactaataaa taattaa 27
 <210> 39
 <211> 1854
 <212> DNA
 <213> H. sapiens

<220>
 <221> CDS
 <222> (15)...(1584)

<400> 39
 tgcattgcac cagg atg tct gtg aaa tgg act tca gta att ttg cta ata 50
 Met Ser Val Lys Trp Thr Ser Val Ile Leu Leu Ile
 1 5 10

caa ctg agc ttt tgc ttt agc tct ggg aat tgt gga aag gtg ctg gtg 98
 Gln Leu Ser Phe Cys Phe Ser Ser Gly Asn Cys Gly Lys Val Leu Val
 15 20 25

PCT/US99/16675

-12-

270	275	280	
gcc aaa ccc ctg cct aag gaa atg gaa gac ttt gta cag agc tct gga Ala Lys Pro Leu Pro Lys Glu Met Glu Asp Phe Val Gln Ser Ser Gly 285 290 295 300			914
gaa aat ggt gtt gtg gtg ttt tct ctg ggg tca atg gtc agt aac atg Glu Asn Gly Val Val Val Phe Ser Leu Gly Ser Met Val Ser Asn Met 305 310 315			962
aca gaa gaa agg gcc aac gta att gca tca gcc ctg gcc cag atc cca Thr Glu Glu Arg Ala Asn Val Ile Ala Ser Ala Leu Ala Gln Ile Pro 320 325 330			1010
caa aag gtt ctg tgg aga ttt gat ggg aat aaa cca gat acc tta ggt Gln Lys Val Leu Trp Arg Phe Asp Gly Asn Lys Pro Asp Thr Leu Gly 335 340 345			1058
ctc aat act cgg ctc tac aag tgg ata ccc cag aat gac ctt cta ggt Leu Asn Thr Arg Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly 350 355 360			1106
cat cca aag acc aga gct ttt ata act cat ggt gga gcc aat ggc atc His Pro Lys Thr Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile 365 370 375 380			1154
tac gag gca atc tac cat ggg atc cct atg gtg ggg att cca ttg ttt Tyr Glu Ala Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe 385 390 395			1202
gcc gat caa cct gat aac att gct cac atg aag gcc agg gga gca gct Ala Asp Gln Pro Asp Asn Ile Ala His Met Lys Ala Arg Gly Ala Ala 400 405 410			1250
gtt aga gtg gac ttc aac aca atg tcg agt aca gac ttg ctg aat gca Val Arg Val Asp Phe Asn Thr Met Ser Ser Thr Asp Leu Leu Asn Ala 415 420 425			1298
ttg aag aga gta att aat gat cct tca tat aaa gag aat gtt atg aaa Leu Lys Arg Val Ile Asn Asp Pro Ser Tyr Lys Glu Asn Val Met Lys 430 435 440			1346
tta tca aga att caa cat gat caa cca gtg aag ccc ctg gat cga gca Leu Ser Arg Ile Gln His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala 445 450 455 460			1394
gtc ttc tgg att gaa ttt gtc atg cgc cac aaa gga gct aaa cac ctt Val Phe Trp Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu 465 470 475			1442
cgg gtt gca gcc cac gac ctc acc tgg ttc cag tac cac tct ttg gat Arg Val Ala Ala His Asp Leu Thr Trp Phe Gln Tyr His Ser Leu Asp 480 485 490			1490
gtg att ggg ttc ctg ctg gtc tgt gtg gca act gtg ata ttt atc gtc Val Ile Gly Phe Leu Leu Val Cys Val Ala Thr Val Ile Phe Ile Val 495 500 505			1538
aca aaa tgt tgt ctg ttt tgt ttc tgg aag ttt gct aga aaa gca a Thr Lys Cys Cys Leu Phe Cys Phe Trp Lys Phe Ala Arg Lys Ala 510 515 520			1584

```

agaaggggaaa aaatgattag ttatatctga gatttgaagc tggaaaacct gataggtgag 1644
actacttcag tttattccag caagaaagat tgtgatgcaa gatttctttc ttcctgagac 1704
aaaaaaaaaa aaagaaaaaa aaatcttttc aaaatttact ttgtcaaata aaaatttggt 1764
tttcagagat ttaccaccca gttcatggtt agaaatattt tgtggcaatg aagaaaacac 1824
tacggaaaat aaaaaataag ataaagcctt                                     1854

```

<210> 40
 <211> 524
 <212> PRT
 <213> H. sapiens

<400> 40

```

Met Ser Val Lys Trp Thr Ser Val Ile Leu Leu Ile Gln Leu Ser Phe
1      5      10      15
Cys Phe Ser Ser Gly Asn Cys Gly Lys Val Leu Val Trp Ala Ala Glu
20     25     30
Tyr Ser His Trp Met Asn Ile Lys Thr Ile Leu Asp Glu Leu Ile Gln
35     40     45
Arg Gly His Glu Val Thr Val Leu Ala Ser Ser Ala Ser Ile Leu Phe
50     55     60
Asp Pro Asn Asn Ser Ser Ala Leu Lys Ile Glu Ile Tyr Pro Thr Ser
65     70     75     80
Leu Thr Lys Thr Glu Leu Glu Asn Phe Ile Met Gln Gln Ile Lys Arg
85     90     95
Trp Ser Asp Leu Pro Lys Asp Thr Phe Trp Leu Tyr Phe Ser Gln Val
100    105    110
Gln Glu Ile Met Ser Ile Phe Gly Asp Ile Thr Arg Lys Phe Cys Lys
115    120    125
Asp Val Val Ser Asn Lys Lys Phe Met Lys Lys Val Gln Glu Ser Arg
130    135    140
Phe Asp Val Ile Phe Ala Asp Ala Ile Phe Pro Cys Ser Glu Leu Leu
145    150    155    160
Ala Glu Leu Phe Asn Ile Pro Phe Val Tyr Ser Leu Ser Phe Ser Pro
165    170    175
Gly Tyr Thr Phe Glu Lys His Ser Gly Gly Phe Ile Phe Pro Pro Ser
180    185    190
Tyr Val Pro Val Val Met Ser Glu Leu Thr Asp Gln Met Thr Phe Met
195    200    205
Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr Phe Asp Phe Trp Phe
210    215    220
Glu Ile Phe Asp Met Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val Leu
225    230    235    240
Gly Arg Pro Thr Thr Leu Ser Glu Thr Met Gly Lys Ala Asp Val Trp
245    250    255
Leu Ile Arg Asn Ser Trp Asn Phe Gln Phe Pro Tyr Pro Leu Leu Pro
260    265    270
Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro Leu
275    280    285
Pro Lys Glu Met Glu Asp Phe Val Gln Ser Ser Gly Glu Asn Gly Val
290    295    300
Val Val Phe Ser Leu Gly Ser Met Val Ser Asn Met Thr Glu Glu Arg
305    310    315    320
Ala Asn Val Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val Leu
325    330    335
Trp Arg Phe Asp Gly Asn Lys Pro Asp Thr Leu Gly Leu Asn Thr Arg
340    345    350
Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr
355    360    365
Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile Tyr Glu Ala Ile
370    375    380
Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe Ala Asp Gln Pro
385    390    395    400

```

```
<210> 42
<211> 1340
<212> DNA
<213> H. sapiens
```

<220>

<221> exon

<222> (668)...(816)

<400> 42

atagtttttg	gaactaggcc	cctttattag	aacatatgag	acaattaagg	tggagtacaa	60
tttttatttc	ataatttctc	aaaaatttct	agctataatg	tacaaatata	tttacttaaa	120
aatattatta	agatccttagc	ttgaatctaa	aagagtagtt	ggtacaagga	tttcagccat	180
actctcaaca	tagtccacag	ttcacttgaa	ccaaagataa	aagaattagc	ttaatgagtt	240
gtgtaaaacta	gactatttct	tagaaaaatta	tttttatggg	tagagtagaa	ttaattgatt	300
atggagctca	aagagttgtt	taaatgtccg	tatgctacta	ttgaagcttt	aagagaaaag	360
aaattttatg	tttaactttc	tatggctcat	tttaataatt	gtttatgatt	atgagcatac	420
tgatgcgaca	ttagagatgt	agcttaacct	cacaattctc	ctactacttt	gtctttctta	480
taaatacaca	tgggcaaaat	atgtaataca	taaaatttaa	ttatatctat	atatgaatat	540
gtgtatatat	ttttcaaagc	acagatatatt	gcctacattt	ttgcctacat	tattctaacc	600
cctttcagaa	atttacctaa	agtaattatc	tttgtgtcatc	cacctttttt	ttttctattc	660
ctgtcaggaa	gaccactac	attatctgag	acaatgggga	aagctgacgt	atggcttatt	720
cgaaactcct	ggaattttca	gtttccatat	ccactcttac	caaagtgtga	ttttgttgga	780
ggactccact	gcaaacctgc	caaaccctcg	cctaaggtaa	acatactttt	gttggtttta	840
ttttgttggc	tttgaatttt	cagtagaaat	gattctatag	tcttctttca	gagtgtttga	900
cttactactga	aagaaagatg	ggaaatgggt	ggggtaaagc	agataccaat	tagaaactca	960
tgtgcacgtt	aataccatca	cacgtatatg	agttttatga	gtattacaaa	tagagaggaa	1020
tactaaggag	actttgaaaa	taggggttgg	taaattaaag	tcttcattat	gcaataacct	1080
agaaggtatt	ggtcatccaa	tcaaataata	ttacaaaagg	gattagcaca	aaacacaggt	1140
aagtcagaa	ttttcagaga	aaaaaataga	cacagtttct	gtccccacat	accttacatt	1200
ctacttcaaa	agatagaata	tgtgcaagta	ataaaaatta	tataaaaact	attatctgaa	1260
ggaaaaacgc	aataccaaga	aagcatcagt	ggagataata	gaaagtatcc	tgcagtcact	1320
gattagtaag	atgggtaccg					1340

<210> 43

<211> 1822

<212> DNA

<213> H. sapiens

<220>

<221> exon

<222> (732)...(863)

<400> 43

tatatacaat	gtctgtatga	taaatgagac	tcctggcact	aattcataga	aattccaaat	60
tacattacca	gactccagaa	tgtcagcggg	tcttaaccac	cagcttttat	ttattttatt	120
tttttttagt	tttgaaaaac	taccagaaaa	ctctgaacaa	actttaagtg	aagtataaag	180
cattgtagag	aaacataaat	gtagatataa	aattatccca	actgtgagta	gcttatcctc	240
agagctcata	gttagggaag	taaaccacta	actgtttcca	actaagagaa	ttctacagaa	300
aacctgcctg	aaataaacac	aagggtattt	gtagaacaac	aatataggat	taaagctgag	360
tggteccact	ttccaagaac	ctatattagt	aacttttagt	atgaaagtga	agagtcgtgt	420
attaatat	tttaacattat	ctccctgaca	acaatgtaat	agctccattt	cttttctccc	480
ttacacacat	gcacacaaat	acatacacat	acacacatat	ttacacaaat	atccttaaca	540
gcatccacct	atctcatatt	atacatctac	ttgcaaaaaa	actgagtgat	tgggtcagtt	600
aaaaaatatt	atttactcca	ataattcctc	aaaatactgg	attttctctc	tttagtaatt	660
tgcaccaatt	cttttggtag	tgcccgtgtg	gctaatactc	ttttgtgatg	aagcaaatc	720
tttcttcaca	ggaaatggaa	gactttgtac	agagctctgg	agaaaaatgg	gttgtgtgtg	780
tttctctggg	gtcaatggtc	agtaacatga	cagaagaaag	ggccaacgta	attgcatcag	840
ccctgggccc	gatcccacaa	aaggttaagat	gaagtgcctt	actggtgtgg	aaaactactg	900
aaagaggctg	ttaaagtgtg	aagtaatcca	attatagaaa	cttctgataa	atgtgaagtt	960
gaccaaaggt	tgaaaaatta	gaacaaggat	aatcttgagg	aaactatgag	aagtttgaaa	1020
attgtggttg	catttttttt	taaatggtgt	taagtatgaa	cattccccta	tgtaaatatg	1080
ctgacaataa	attgaatgga	gaaaggtatt	taaaaagtgt	ttggagactt	ctcacctcct	1140
gtccataaaa	ttttgaattg	tgtatgtgat	ctacatagga	aaggatatta	aagagtagat	1200
tgaactcttc	catagctgaa	tatagcctta	aatatgcttg	tatagcatcc	accgacagaa	1260
gtaatagttg	tgcctcagac	ttaggggttg	catgtggccc	tggaggagtt	actacccttg	1320
gtatgcatga	gtagttccta	ttagcatcag	tgggaactca	gtactccata	tgtattcaca	1380

aaaggcaact	tgagaccac	agttattttt	aatttctgat	attaacactc	atacactg	1440
ctgaatttaa	ctcaatatat	ttcagtttaag	tgaaaatggt	gcttaatgta	gtcttttagaa	1500
tgactttcag	gtgttttcac	aaaaaacgta	tatccagaac	tgtgtccttt	tagaaataca	1560
agtaaaattt	ttgataatta	gcttcaaaac	agttttccta	atctcagcag	tatccaatga	1620
gtgaagaaca	cttgactgac	tcttgggtca	cctctattac	ttattgtact	ctggaagctc	1680
ttggtgaatg	tttacgatta	tgggatgtag	tatttctggt	tgcactttaa	gtcaaatgct	1740
tgtataaaat	acgtgacaac	aaatggagaa	tattggctct	gtagtagtt	atgcggtata	1800
ttctctgttt	aaggatcttt	gg				1822

<210> 44
 <211> 1591
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (138)...(225)

<221> exon
 <222> (1067)...(1286)

<400> 44						
attctattta	cattagcctt	tgagtagttc	ttatttacta	acatcccttg	atctcattcc	60
tactctttat	acagtttctca	cattctataa	cttttgaatt	ccactcatgg	aataaaatat	120
tttctttatt	gtaacagggtt	ctgtggagat	ttgatgggaa	taaaccagat	accttaggtc	180
tcaatactcg	gctctacaag	tggatacccc	agaatgacct	tctaggtaag	actctggtga	240
acaaatactg	aatatattag	taacagcaca	ttagagtgtt	aatagttcat	catgaaacaa	300
gcttattgaa	tatttggttaa	ggaaaaacaa	aatgtaactt	ctttatattg	attttccagt	360
cttaagggag	aaagaatata	ttataatttt	tggcatttta	tgatatacac	ccacattctt	420
tatagtctga	atcgggggaa	tctttatttc	agggtgttatt	atatctcaca	aaatttttca	480
ataacttctt	gggctgtctc	tctgtctcct	atttctacaa	ctttacacct	gtttttttcc	540
tctcccgag	ggttatttga	aatgccacta	aaaataatag	ctcttctatc	accagtgaat	600
ctgtattttc	tgaagaatta	aactgctaata	cttaatcata	cagtgtgat	acatttcacg	660
atgaagtgtg	acctgtcctt	cctcaatcct	agcaccacca	ccaaaccact	gcctgctgcc	720
ttgcccaccc	catatatcac	actctgtgac	tgtcacttaa	aataagagtt	cacttcatgc	780
ctatctcttt	gctgtcttct	tttttgacaa	tttttgaaat	ctagaatgca	atttttcatt	840
agcccaactg	gaaatcttgt	attgttttgc	agtctgaagt	cacacacacc	gtatagcctt	900
cagttacata	cccagtacaa	gtacgtgttt	tttctccga	agtctgaaac	acaattttta	960
tttagttcag	tgttttagct	ggaaaacact	gtcactttca	gagcctttca	ttgtgcatct	1020
cattttattc	ctataggtaa	ttttgtctaa	attcatccaa	tcctagggtca	tccaaagacc	1080
agagctttta	taactcatgg	tggagccaat	ggcatctacg	aggcaatcta	ccatgggac	1140
cctatggtgg	ggattccatt	gtttgccgat	caacctgata	acattgctca	catgaaggcc	1200
aggggagcag	ctgttagagt	ggacttcaac	acaatgtcga	gtacagactt	gctgaatgca	1260
ttgaagagag	taattaatga	tccttcgtga	gtagaacaat	atttttcact	agggtggtatt	1320
tacagatagc	ttctcttgct	aatagttagt	gtgagtttca	tcctttttat	aagagactaa	1380
ttttgaaaga	atttaaatgat	ttaaccaatc	tgaatctgct	ttttattttt	ataagttatt	1440
taaaaattga	atttgaacaa	catacatcta	aagaatagcc	agttagtga	acaattttct	1500
acacaaaaat	aattttaaaa	ggatatagat	aatacaaaaa	atacatttct	taaaaatttg	1560
acataattaa	tccatagaag	aaaggaagaa	t			1591

<210> 45
 <211> 596
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (19)...(549)

<400> 45						
ctttattttt	atctttcaga	tataaagaga	atgttatgaa	attatcaaga	attcaacatg	60
atcaaccagt	gaagcccctg	gatcgagcag	tcttctggat	tgaatttgct	atgcgccaca	120

```

aaggagctaa acaccttcgg gttgcagccc acgacctcac ctggttccag taccactctt 180
tggatgtgat tgggttcctg ctggtctgtg tggcaactgt gatatttate gtcacaaaat 240
gttgtctgtt ttgtttctgg aagtttgcta gaaaagcaaa gaagggaataaatgattagt 300
tatacttgag atttgaagct ggaaaacctg ataggtgaga ctacttcagt ttattccagc 360
aagaaagatt gtgatgcaag atttctttct tcctgagaca aaaaaaaaaa aagaaaaaaaaa 420
aatcttttca aaatttactt tgtcaaataa aaatttggtt ttcagagatt taccacccag 480
ttcatgggta gaaatatttt gtggcaatga agaaaacact acggaaaata aaaaataaga 540
taaagcctta tgagctcgta ttgaaatttg ttgaacttat atcgcggtac ctactg 596

```

```

<210> 46
<211> 20
<212> DNA
<213> H. sapiens

```

```

<400> 46
cttggctaatt ttatctttgg 20

```

```

<210> 47
<211> 19
<212> DNA
<213> H. sapiens

```

```

<400> 47
cccactaccc tgactttat 19

```

```

<210> 48
<211> 20
<212> DNA
<213> H. sapiens

```

```

<400> 48
ggacataacc atgagaaatg 20

```

```

<210> 49
<211> 19
<212> DNA
<213> H. sapiens

```

```

<400> 49
agctctgctt caaagacac 19

```

```

<210> 50
<211> 21
<212> DNA
<213> H. sapiens

```

```

<400> 50
tgtccgtatg ctactattga a 21

```

```

<210> 51
<211> 21
<212> DNA
<213> H. sapiens

```

```

<400> 51
tgtgctaatac cctttgtaaa t 21

```

```

<210> 52
<211> 22
<212> DNA
<213> H. sapiens

```


<400> 52
tttttttttc tattcctgtc ag 22

<210> 53
<211> 17
<212> DNA
<213> H. sapiens

<400> 53
ctttacccca cccattt 17

<210> 54
<211> 20
<212> DNA
<213> H. sapiens

<400> 54
cccttgatct cattcctact 20

<210> 55
<211> 24
<212> DNA
<213> H. sapiens

<400> 55
aactggctat tctttagatg tatg 24

<210> 56
<211> 25
<212> DNA
<213> H. sapiens

<400> 56
cattcctact ctttatacag ttctc 25

<210> 57
<211> 17
<212> DNA
<213> H. sapiens

<400> 57
cccccgattc agactat 17

<210> 58
<211> 20
<212> DNA
<213> H. sapiens

<400> 58
cccttgatct cattcctact 20

<210> 59
<211> 24
<212> DNA
<213> H. sapiens

<400> 59
aactggctat tctttagatg tatg 24

<210> 60
<211> 18
<212> DNA

<213> H. sapiens
<400> 60
tcctccgaag tctgaaac 18
<210> 61
<211> 23
<212> DNA
<213> H. sapiens
<400> 61
tataaaaagg atgaaactca cac 23
<210> 62
<211> 18
<212> DNA
<213> H. sapiens
<400> 62
caagccccca agttatgt 18
<210> 63
<211> 20
<212> DNA
<213> H. sapiens
<400> 63
cagtaggatc cgcgatataa 20
<210> 64
<211> 20
<212> DNA
<213> H. sapiens
<400> 64
tgtgaggggt tttgtctgta 20
<210> 65
<211> 20
<212> DNA
<213> H. sapiens
<400> 65
ccgcgatata agttcaacaa 20
<210> 66
<211> 20
<212> DNA
<213> H. sapiens
<400> 66
ggacataacc atgagaaatg 20
<210> 67
<211> 19
<212> DNA
<213> H. sapiens
<400> 67
ttaagagcgg atgagttgt 19
<210> 68

<211> 20
<212> DNA
<213> H. sapiens

<400> 68
tcatcatgca acagattaag 20

<210> 69
<211> 20
<212> DNA
<213> H. sapiens

<400> 69
cactacaggg aaaaatagca 20

<210> 70
<211> 20
<212> DNA
<213> H. sapiens

<400> 70
accctttgtg tacagtctca 20

<210> 71
<211> 19
<212> DNA
<213> H. sapiens

<400> 71
agctctgctt caaagacac 19

<210> 72
<211> 21
<212> DNA
<213> H. sapiens

<400> 72
ttgcctacat tattctaacc c 21

<210> 73
<211> 17
<212> DNA
<213> H. sapiens

<400> 73
ctttaccca cccattt 17

<210> 74
<211> 25
<212> DNA
<213> H. sapiens

<400> 74
cattcctact ctttatacag ttctc 25

<210> 75
<211> 17
<212> DNA
<213> H. sapiens

<400> 75
cccccgattc agactat 17

<210> 76
<211> 25
<212> DNA
<213> H. sapiens

<400> 76
cattcctact ctttatacag ttctc 25

<210> 77
<211> 17
<212> DNA
<213> H. sapiens

<400> 77
cccccgattc agactat 17

<210> 78
<211> 18
<212> DNA
<213> H. sapiens

<400> 78
tcctccgaag tctgaaac 18

<210> 79
<211> 23
<212> DNA
<213> H. sapiens

<400> 79
tataaaaagg atgaaactca cac 23

<210> 80
<211> 20
<212> DNA
<213> H. sapiens

<400> 80
tctgaggggt tttgtctgta 20

<210> 81
<211> 22
<212> DNA
<213> H. sapiens

<400> 81
ttttttgtct caggaagaaa ga 22

<210> 82
<211> 24
<212> DNA
<213> H. sapiens

<400> 82
aaaaaaagaa aaaaaaatct ttctc 24

<210> 83
<211> 20
<212> DNA
<213> H. sapiens

<400> 83 ccgcgatata agttcaacaa	20
<210> 84 <211> 22 <212> DNA <213> H. sapiens	
<400> 84 tgcattgcac caggatgtct gt	22
<210> 85 <211> 21 <212> DNA <213> H. sapiens	
<400> 85 gcattgcacc aagatgtctg t	21
<210> 86 <211> 23 <212> DNA <213> H. sapiens	
<400> 86 tcctggatga gcttattcag aga	23
<210> 87 <211> 23 <212> DNA <213> H. sapiens	
<400> 87 tcctggatga gcctattcag aga	23
<210> 88 <211> 21 <212> DNA <213> H. sapiens	
<400> 88 cattttgggtt atatttttca c	21
<210> 89 <211> 21 <212> DNA <213> H. sapiens	
<400> 89 cattttgggtt ttatttttca c	21
<210> 90 <211> 21 <212> DNA <213> H. sapiens	
<400> 90 cataactaga aagttctgta a	21
<210> 91 <211> 21 <212> DNA	

<213> H. sapiens	
<400> 91	
cataactagg aagttctgta a	21
<210> 92	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 92	
cctggctaca cttttgaaaa	20
<210> 93	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 93	
cctggctaca tttttgaaaa	20
<210> 94	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 94	
gaagaccac tacattatct g	21
<210> 95	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 95	
gaagaccac tacgttatct g	21
<210> 96	
<211> 26	
<212> DNA	
<213> H. sapiens	
<400> 96	
aattttcagt ttccatatcc actctt	26
<210> 97	
<211> 26	
<212> DNA	
<213> H. sapiens	
<400> 97	
aattttcagt ttcccatcc actctt	26
<210> 98	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 98	
taggtctcaa tactcggtc ta	22
<210> 99	

```

      <211> 22
      <212> DNA
      <213> H. sapiens

      <400> 99
taggtctcaa tactcggtg ta                                22

      <210> 100
      <211> 19
      <212> DNA
      <213> H. sapiens

      <400> 100
tacaagtgga taccacaga                                19

      <210> 101
      <211> 19
      <212> DNA
      <213> H. sapiens

      <400> 101
tataagtgga taccacaga                                19

      <210> 102
      <211> 26
      <212> DNA
      <213> H. sapiens

      <400> 102
gggagaaaga atacattata attttt                        26

      <210> 103
      <211> 25
      <212> DNA
      <213> H. sapiens

      <400> 103
gggagaaaga atactataa ttttt                        25

      <210> 104
      <211> 21
      <212> DNA
      <213> H. sapiens

      <400> 104
ttccattgtt tgccgatcaa c                            21

      <210> 105
      <211> 21
      <212> DNA
      <213> H. sapiens

      <400> 105
ttccattgtt tgctgatcaa c                            21

      <210> 106
      <211> 21
      <212> DNA
      <213> H. sapiens

      <400> 106
gaatgcattg aagagagtaa t                            21

```

<210> 107
 <211> 21
 <212> DNA
 <213> H. sapiens

 <400> 107
 gaatgcattg cagagagtaa t 21

 <210> 108
 <211> 22
 <212> DNA
 <213> H. sapiens

 <400> 108
 ctggtctgtg tggcaactgt ga 22

 <210> 109
 <211> 22
 <212> DNA
 <213> H. sapiens

 <400> 109
 ctggtctgtg tggcgactgt ga 22

 <210> 110
 <211> 19
 <212> DNA
 <213> H. sapiens

 <400> 110
 taagataaag ccttatgag 19

 <210> 111
 <211> 19
 <212> DNA
 <213> H. sapiens

 <400> 111
 taagataaag acttatgag 19

 <210> 112
 <211> 1976
 <212> DNA
 <213> H. sapiens

 <220>
 <221> CDS
 <222> (11)...(1598)

 <400> 112
 taagaccagg atg tct ctg aaa tgg acg tca gtc ttt ctg ctg ata cag 49
 Met Ser Leu Lys Trp Thr Ser Val Phe Leu Leu Ile Gln
 1 5 10

 ctc agt tgt tac ttt agc tct gga agc tgt gga aag gtg cta gtg tgg 97
 Leu Ser Cys Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp
 15 20 25

 ccc aca gaa tac agc cat tgg ata aat atg aag aca atc ctg gaa gag 145
 Pro Thr Glu Tyr Ser His Trp Ile Asn Met Lys Thr Ile Leu Glu Glu
 30 35 40 45

ctt gtt cag agg ggt cat gag gtg act gtg ttg aca tct tcg gct tct Leu Val Gln Arg Gly His Glu Val Thr Val Leu Thr Ser Ser Ala Ser 50 55 60	193
act ctt gtc aat gcc agt aaa tca tct gct att aaa tta gaa gtt tat Thr Leu Val Asn Ala Ser Lys Ser Ser Ala Ile Lys Leu Glu Val Tyr 65 70 75	241
cct aca tct tta act aaa aat gat ttg gaa gat tct ctt ctg aaa att Pro Thr Ser Leu Thr Lys Asn Asp Leu Glu Asp Ser Leu Leu Lys Ile 80 85 90	289
ctc gat aga tgg ata tat ggt gtt tca aaa aat aca ttt tgg tca tat Leu Asp Arg Trp Ile Tyr Gly Val Ser Lys Asn Thr Phe Trp Ser Tyr 95 100 105	337
ttt tca caa tta caa gaa ttg tgt tgg gaa tat tat gac tac agt aac Phe Ser Gln Leu Gln Glu Leu Cys Trp Glu Tyr Tyr Asp Tyr Ser Asn 110 115 120 125	385
aag ctc tgt aaa gat gca gtt ttg aat aag aaa ctt atg atg aaa cta Lys Leu Cys Lys Asp Ala Val Leu Asn Lys Lys Leu Met Met Lys Leu 130 135 140	433
caa gag tca aag ttt gat gtc att ctg gca gat gcc ctt aat ccc tgt Gln Glu Ser Lys Phe Asp Val Ile Leu Ala Asp Ala Leu Asn Pro Cys 145 150 155	481
ggg gag cta ctg gct gaa cta ttt aac ata ccc ttt ctg tac agt ctt Gly Glu Leu Leu Ala Glu Leu Phe Asn Ile Pro Phe Leu Tyr Ser Leu 160 165 170	529
cga ttc tct gtt ggc tac aca ttt gag aag aat ggt gga gga ttt ctg Arg Phe Ser Val Gly Tyr Thr Phe Glu Lys Asn Gly Gly Gly Phe Leu 175 180 185	577
ttc cct cct tcc tat gta cct gtt gtt atg tca gaa tta agt gat caa Phe Pro Pro Ser Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln 190 195 200 205	625
atg att ttc atg gag agg ata aaa aat atg ata cat atg ctt tat ttt Met Ile Phe Met Glu Arg Ile Lys Asn Met Ile His Met Leu Tyr Phe 210 215 220	673
gac ttt tgg ttt caa att tat gat ctg aag aag tgg gac cag ttt tat Asp Phe Trp Phe Gln Ile Tyr Asp Leu Lys Lys Trp Asp Gln Phe Tyr 225 230 235	721
agt gaa gtt cta gga aga ccc act aca tta ttt gag aca atg ggg aaa Ser Glu Val Leu Gly Arg Pro Thr Thr Leu Phe Glu Thr Met Gly Lys 240 245 250	769
gct gaa atg tgg ctc att cga acc tat tgg gat ttt gaa ttt cct cgc Ala Glu Met Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Arg 255 260 265	817
cca ttc tta cca aat gtt gat ttt gtt gga gga ctt cac tgt aaa cca Pro Phe Leu Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro 270 275 280 285	865
gcc aaa ccc ctg cct aag gaa atg gaa gag ttt gtg cag agc tct gga	913

Ala Lys Pro Leu Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly	
290 295 300	
gaa aat ggt att gtg gtg ttt tct ctg ggg tcg atg atc agt aac atg	961
Glu Asn Gly Ile Val Val Phe Ser Leu Gly Ser Met Ile Ser Asn Met	
305 310 315	
tca gaa gaa agt gcc aac atg att gca tca gcc ctt gcc cag atc cca	1009
Ser Glu Glu Ser Ala Asn Met Ile Ala Ser Ala Leu Ala Gln Ile Pro	
320 325 330	
caa aag gtt cta tgg aga ttt gat ggc aag aag cca aat act tta ggt	1057
Gln Lys Val Leu Trp Arg Phe Asp Gly Lys Lys Pro Asn Thr Leu Gly	
335 340 345	
tcc aat act cga ctg tac aag tgg tta ccc cag aat gac ctt ctt ggt	1105
Ser Asn Thr Arg Leu Tyr Lys Trp Leu Pro Gln Asn Asp Leu Leu Gly	
350 355 360 365	
cat ccc aaa acc aaa gct ttt ata act cat ggt gga acc aat ggc atc	1153
His Pro Lys Thr Lys Ala Phe Ile Thr His Gly Gly Thr Asn Gly Ile	
370 375 380	
tat gag gcg atc tac cat ggg atc cct atg gtg ggc att ccc ttg ttt	1201
Tyr Glu Ala Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe	
385 390 395	
gcg gat caa cat gat aac att gct cac atg aaa gcc aag gga gca gcc	1249
Ala Asp Gln His Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala	
400 405 410	
ctc agt gtg gac atc agg acc atg tca agt aga gat ttg ctc aat gca	1297
Leu Ser Val Asp Ile Arg Thr Met Ser Ser Arg Asp Leu Leu Asn Ala	
415 420 425	
ttg aag tca gtc att aat gac cct gtc tat aaa gag aat gtc atg aaa	1345
Leu Lys Ser Val Ile Asn Asp Pro Val Tyr Lys Glu Asn Val Met Lys	
430 435 440 445	
tta tca aga att cat cat gac caa cca atg aag ccc ctg gat cga gca	1393
Leu Ser Arg Ile His His Asp Gln Pro Met Lys Pro Leu Asp Arg Ala	
450 455 460	
gtc ttc tgg att gag ttt gtc atg cgc cac aaa gga gcc aag cac ctt	1441
Val Phe Trp Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu	
465 470 475	
cga gtc gca gct cac aac ctc acc tgg atc cag tac cac tct ttg gat	1489
Arg Val Ala Ala His Asn Leu Thr Trp Ile Gln Tyr His Ser Leu Asp	
480 485 490	
gtg ata gca ttc ctg ctg gcc tgc gtg gca act gtg ata ttt atc atc	1537
Val Ile Ala Phe Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile	
495 500 505	
aca aaa ttt tgc ctg ttt tgt ttc cga aag ctt gcc aaa aca gga aag	1585
Thr Lys Phe Cys Leu Phe Cys Phe Arg Lys Leu Ala Lys Thr Gly Lys	
510 515 520 525	
aag aag aaa aga g attagttata tcaaaagcct gaagtggaat gactgaaaga	1638
Lys Lys Lys Arg	

```

tgggactcct cctttatttc agcatggagg gttttaaatg gaggatttcc tttttcctgt 1698
gacaaaacat cttttcacta cttaccttgt taagacaaaa tttattttcc agggatttaa 1758
tacgtacttt agttggaatt attctatgtc aatgattttt aagctatgaa aaatacaatg 1818
gggggaagga tagcatttgg agatatacct aatgttaaat gacgagttac tggatgcagc 1878
acgccaacat ggcacatgta tacatatgta gctaacctca cgttgtgcac atgtacccta 1938
aaacttaaag tataatttaa aaaaagcaaa ggggtaccg 1976

```

<210> 113

<211> 530

<212> PRT

<213> H. sapiens

<400> 113

```

Met Ser Leu Lys Trp Thr Ser Val Phe Leu Leu Ile Gln Leu Ser Cys
1      5      10      15
Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp Pro Thr Glu
20      25      30
Tyr Ser His Trp Ile Asn Met Lys Thr Ile Leu Glu Glu Leu Val Gln
35      40      45
Arg Gly His Glu Val Thr Val Leu Thr Ser Ser Ala Ser Thr Leu Val
50      55      60
Asn Ala Ser Lys Ser Ser Ala Ile Lys Leu Glu Val Tyr Pro Thr Ser
65      70      75      80
Leu Thr Lys Asn Asp Leu Glu Asp Ser Leu Leu Lys Ile Leu Asp Arg
85      90      95
Trp Ile Tyr Gly Val Ser Lys Asn Thr Phe Trp Ser Tyr Phe Ser Gln
100      105      110
Leu Gln Glu Leu Cys Trp Glu Tyr Asp Tyr Ser Asn Lys Leu Cys
115      120      125
Lys Asp Ala Val Leu Asn Lys Lys Leu Met Met Lys Leu Gln Glu Ser
130      135      140
Lys Phe Asp Val Ile Leu Ala Asp Ala Leu Asn Pro Cys Gly Glu Leu
145      150      155      160
Leu Ala Glu Leu Phe Asn Ile Pro Phe Leu Tyr Ser Leu Arg Phe Ser
165      170      175
Val Gly Tyr Thr Phe Glu Lys Asn Gly Gly Gly Phe Leu Phe Pro Pro
180      185      190
Ser Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln Met Ile Phe
195      200      205
Met Glu Arg Ile Lys Asn Met Ile His Met Leu Tyr Phe Asp Phe Trp
210      215      220
Phe Gln Ile Tyr Asp Leu Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val
225      230      235      240
Leu Gly Arg Pro Thr Thr Leu Phe Glu Thr Met Gly Lys Ala Glu Met
245      250      255
Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Arg Pro Phe Leu
260      265      270
Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro
275      280      285
Leu Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly
290      295      300
Ile Val Val Phe Ser Leu Gly Ser Met Ile Ser Asn Met Ser Glu Glu
305      310      315      320
Ser Ala Asn Met Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val
325      330      335
Leu Trp Arg Phe Asp Gly Lys Lys Pro Asn Thr Leu Gly Ser Asn Thr
340      345      350
Arg Leu Tyr Lys Trp Leu Pro Gln Asn Asp Leu Leu Gly His Pro Lys
355      360      365
Thr Lys Ala Phe Ile Thr His Gly Gly Thr Asn Gly Ile Tyr Glu Ala
370      375      380

```

Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe Ala Asp Gln
 385 390 395 400
 His Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Leu Ser Val
 405 410 415
 Asp Ile Arg Thr Met Ser Ser Arg Asp Leu Leu Asn Ala Leu Lys Ser
 420 425 430
 Val Ile Asn Asp Pro Val Tyr Lys Glu Asn Val Met Lys Leu Ser Arg
 435 440 445
 Ile His His Asp Gln Pro Met Lys Pro Leu Asp Arg Ala Val Phe Trp
 450 455 460
 Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala
 465 470 475 480
 Ala His Asn Leu Thr Trp Ile Gln Tyr His Ser Leu Asp Val Ile Ala
 485 490 495
 Phe Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile Thr Lys Phe
 500 505 510
 Cys Leu Phe Cys Phe Arg Lys Leu Ala Lys Thr Gly Lys Lys Lys
 515 520 525
 Arg Asp
 530

<210> 114
 <211> 2312
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (692)...(1425)

<400> 114
 accctcctgc tcccatctgc catgatcact ggaaaaccct catttatattt ttaaagggtc 60
 cagaaaaatgc taatctatag agatagaaat tagattagtg gttgcctagg gtaggatgga 120
 tgcaaaattt cagagtgggg ggttagagggc tattgtatag aatcttttgg agataatact 180
 gattattgta gtgaaagtaa aattctgtga atatactagg aaacattgaa ctgtacacac 240
 taattggtga gtcataatgt atatgaatta tgtgtcaaca aagttttaga agacattact 300
 tgcaccacga tattaaaaaa tgcggtttga ttgtataat tacttcttct ctctatgtca 360
 agggcaccga acaggcagga gcctctcact tgccactgtt cttaacagta ttataaaata 420
 attacataag acaggttact tacatattct aggtcataaa aattattgct tgactagagt 480
 aattgtaaac ataaaaaac accaaacaca ctaaaataaa tatgagggtca tcaatctttt 540
 gttggtctcc ttggcatgca cctattcaga ctgttagtat tatgtattta cttcaaattt 600
 tagcagttat attttaactt gattgatttt tcctcagata taagtatgag aaatgacaga 660
 aagaaacaac aactggaaaa gaagcattgc ataagaccag gatgtctctg aaatggacgt 720
 cagtctttct gctgatacag ctacagttgt acttttagctc tggaagctgt ggaaagggtc 780
 tagtgtggcc cacagaatac agccattgga taaatatgaa gacaatcctg gaagagcttg 840
 ttcagagggg tcatgaggtg actgtgttga catcttcggc ttctactctt gtcaatgcca 900
 gtaaatcatc tgctattaaa ttagaagttt atcctacatc tttaaactaaa aatgatttgg 960
 aagattctct tctgaaaatt ctcgatagat ggatatatgg tgtttcaaaa aatacatttt 1020
 ggtcatattt ttcacaatta caagaattgt gttgggaata ttatgactac agtaacaagc 1080
 tctgtaaaga tgcagttttg aataagaaac ttatgatgaa actacaagag tcaaagtttg 1140
 atgtcattct ggcagatgcc cttaatccct gtggtgagct actggctgaa ctatttaaca 1200
 taccctttct gtacagtctt cgattctctg ttggctacac atttgagaag aatggtggag 1260
 gatttctgtt cctcctctcc tatgtacctg ttgttatgtc agaattaagt gatcaaatga 1320
 ttttcatgga gaggataaaa aatatgatac atatgcttta ttttgacttt tgggttcaaa 1380
 tttatgatct gaagaagtgg gaccagtttt atagtgaagt tctaggttaag tcatgtgtct 1440
 aactggtgct tattaagttc taacttttct gtgcctttga aggtgagctt atataaata 1500
 aatgtcagaa gatagtgttt ttaagggaata ttatgaattg caaatgtaag atgactatc 1560
 agtctcaaaa atattataga atgttgacct tatagaatca gttagaaccc tggggccatc 1620
 actactacag gacaccacga gagtcataaa ccttcattgt aaagcactaa tgatttcttt 1680
 aaactatcac atatcatttt gctatacatt ttttcatctt taaaaaaagt caatagatac 1740
 ctcaagaaac atcttcatga aggcagacac ataaatttag tatttacaca tatttctaga 1800
 aaaattatca atgcaggatt gaggaatttg tttctcttgg agttcctcag tttcctcatt 1860

tagaaattaa	attttgtttt	tcatgtgaaga	aggattcctt	cacagttgag	taatatagtg	1920
gctctactcc	agaaacagaa	gcctaaaaact	tgagatttct	aatgtttata	cattccttca	1980
ataacagggt	gacaattatt	tctttcaaaa	actgaaatct	tggtgaaagt	gaacatctaa	2040
gttttaactc	atattttatt	aaactgcatc	tctccatcaa	agaaaaatag	ggccaaatta	2100
agggagagca	catatctcta	tgtcaataaa	ttctgaaaat	gttttaattc	tcatttgtaa	2160
atataattat	tttaaaaatc	taattatatt	aagatcttac	gatgaaccaa	gacagtagta	2220
ggtgtaaaaga	tttcagtgtt	gagctcaaaa	aactcatggt	ttactttgag	aaccaaggat	2280
caagggtctag	cttaataaac	tgtagacact	ag			2312

<210> 115
 <211> 1021
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (413)...(565)

<400> 115						
accatgatcc	aatcacctgc	cactgggtcc	ctccctggac	acatggggat	tatggggatt	60
ataattcaag	atgagaggag	atttggtggtg	ggacagtcaa	accatattag	tgactttatt	120
taataattat	ttatgattgt	gaatatactg	atgttacatt	aaagatgtga	tttcttctta	180
cagatctctg	aatacattgc	cttccttata	tatacatatg	agcaacatat	gcaataaata	240
aaatctaaat	tatgactata	tataaatgta	tttatatata	ttttatcaat	gcacagacat	300
tttatatatg	tttgggtatg	ttattccaag	tcctttcagg	aaaataacctg	catattcaaa	360
taacaattct	cgtgttagct	accttttgtt	ttgttttgtt	tttttccatc	aggaagaccc	420
actacattat	ttgagacaat	ggggaaaagct	gaaatgtggc	tcattcgaac	ctattgggat	480
tttgaatttc	ctcgccatt	cttaccaaat	gttgattttg	ttggaggact	tcactgtaaa	540
ccagccaaac	ccctgcctaa	ggtaaatgta	ttcttgtttc	atttgtttgc	ttgacatttt	600
cagaaggaat	ggctggatat	gtttctttca	gagtgtttaa	ctcagagtga	ggggaatatg	660
ggaggtcaaa	aacaaggact	tgccattaga	aaatcatata	tttctgtagt	atcacaagta	720
tgtgaatggt	attatcatta	aagaccaaag	aggtttacta	gggagatttt	gaaaacaggg	780
ttggttaaag	taaggccttc	attgtgccac	ccaaaagata	gtatgattca	tttcttcaaa	840
aaatatttgt	agagtgatta	atacaaacca	caggtaagtgt	ctggattttc	agagaataaa	900
ggtagcacag	tttctgtctc	ctcatgcctt	acattgtact	ttgaaagata	gaataaaaac	960
aagtgaaaaa	gaaaagtcta	aaaagtgtta	ttaaaggaaa	accacaatga	taaagaaata	1020
t						1021

<210> 116
 <211> 480
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (43)...(174)

<400> 116						
tgctgttgct	cttttctgat	agaacaaatt	ctttcttcac	aggaaatgga	agagtttgtg	60
cagagctctg	gagaaaaatg	tattgtggtg	ttttctctgg	ggcagatgat	cagtaacatg	120
tcagaagaaa	gtgccaacat	gattgcatca	gcccttgccc	agatcccaca	aaagggttaga	180
taaagtgcct	taactgtgga	tggtactata	atgaatctgt	taaactcttc	aagagtccat	240
tacagaaatg	ttctgcctga	aaatttaact	gctatgatag	ttctaattat	ctcagacatc	300
tgttcaaaag	aaaaacatat	atggaagatc	ttaaaatcat	aaagagagga	gttttggttg	360
ataataacgt	tggcattaat	attgtgatca	gaaggaaaata	tatttaagag	gtgctagtga	420
agtttggtat	tatcatggtg	tcgtagcatg	tacatagaaa	tcactaaatt	ctgccctgtc	480

<210> 117
 <211> 1602
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (368) ... (455)

<221> exon
 <222> (1295) ... (1514)

<400> 117

tgagtc	caagg	gctgact	ttg	aatagaat	gg	gaggtag	ggt	tgcccta	agc	agctta	actt	60
ttccctt	tag	catagag	ttt	gggttg	ccaa	gatttat	ttt	cctttc	acaa	tctcat	gtgt	120
ctagctat	ta	tgtagaa	at	gtcatt	at	ctttat	atac	aaaatt	gatt	ataaaa	agtaa	180
cgacatt	aaa	cgtggg	tatt	caactt	ac	caaact	ttta	gtagtt	ctca	ttactt	gaca	240
tcactt	cttc	ttattt	cttc	atcttt	tata	tggatta	act	aactg	attat	taatct	cttc	300
agaatt	ctaa	catgct	atgt	ttttag	agtt	ctattc	attg	aacaag	atat	tttcct	tgcc	360
ctaacag	ggt	ctatgg	agat	ttgatg	gcaa	gaagcca	aat	acttt	aggt	ccaata	ctcg	420
actgtac	aag	tggtt	acccc	agaatg	acct	tcttg	gtaag	attctg	gaga	acaaac	agtg	480
aatatatt	tag	taacag	caaa	ttggag	tgat	aatagt	tcaa	cataaa	acaa	acatat	ttag	540
catttatt	at	tgaaaa	acta	aaaaaca	aat	caaatt	ttaac	tacttt	tatat	ttattt	tcca	600
gtcttag	tat	aaaaa	gaatg	cactata	gta	gttggc	attt	tattac	atac	agtcac	attc	660
tttatg	gtca	gaataa	aaat	ctcttt	gttc	aggtg	taatt	tcctct	caca	ggtttt	aaat	720
aacatoc	tgg	at	tttctgtc	tgtctc	ctat	ttatgc	cagct	ttacct	ctgt	tctttc	ccct	780
actgcag	ggt	tatttca	aca	ggcact	gaaa	aatagc	ggac	actttt	ctat	taccag	tgac	840
tctact	tttt	atggga	ataa	ataacca	atc	tttatc	atga	taaaat	gata	acacatt	tca	900
tgatgat	gca	taaccg	gtcc	ttcctc	agcc	ccacct	ccac	cctact	ccct	gctgc	ctttt	960
aaaaaaa	att	aaatat	ttta	aatatt	ttta	gtattt	aaat	attttt	ttaa	tatgta	aatg	1020
tgacct	catt	atttata	ata	cttaaa	agac	cacgtt	cttg	tatacc	caat	cttatt	cttt	1080
tttttt	gcac	atttta	attt	tttaatt	taag	aatatg	cttt	ttcatt	tttg	tcacct	ggca	1140
attctt	ctga	aaattg	aaaa	caattt	caat	gcagtt	tttg	gggtata	aatg	ttacct	aggg	1200
aacagt	tttg	ctttaag	ttc	cttat	attgt	gcattt	ctta	ttcaatt	ctc	atacct	tgta	1260
attaata	att	ttgttaa	aaat	gcatac	cactt	ttaggt	catc	ccaaa	accaa	agcttt	tata	1320
actcat	ggtg	gaacca	atgg	catct	atgag	gcgat	ctacc	atggg	atccc	tatggt	gggc	1380
attccct	tgt	ttgcgg	atca	acatg	ataac	attgtc	caca	tgaaa	gccaa	gggag	cagcc	1440
ctcagt	gtg	acatcag	gac	catgtc	caagt	agagatt	tg	tcaatg	catt	gaagt	cagtc	1500
attaatg	acc	ctgtgt	gagt	attacag	ttt	tgtgac	cagg	tggtatt	tat	aaatt	tttt	1560
gtcaac	agtg	aatatg	aatt	ttaacc	ggt	tttaag	agac	ta				1602

<210> 118
 <211> 978
 <212> DNA
 <213> H. sapiens

<220>
 <221> exon
 <222> (326) ... (978)

<400> 118

caaaaag	atc	attctca	aat	tccattt	cca	ctatctt	act	tatagc	actt	agaatg	gctc	60
ataatat	tttt	ctgctcc	aga	aaacatt	taac	tttccc	accg	aaaatt	ccat	ttttc	at	120
taaagg	tatt	tgtcagt	gat	aaaact	ccaa	tttaaaa	acc	aaactt	tctg	taatg	acatg	180
aattaaa	aca	ttgaaat	ttc	atgcc	aattc	agtga	cactt	acttt	caatc	attt	gtgtg	240
cactttt	caa	agaccat	cca	tagactt	gat	atgctt	aaagc	aataa	attta	ctttt	aatgt	300
tgatatt	cttt	atattt	atcc	ttcagc	tata	aagaga	atgt	catgaa	atta	tcaaga	attc	360
atcatg	acca	accaat	gaag	cccctg	gatc	gagcag	tctt	ctggat	tgag	tttgt	catgc	420
gccacaa	agg	agcca	agcac	cttcg	agtcg	cagctc	acaa	cctcac	ctgg	atccag	tacc	480
actcttt	gga	tgtgat	agca	ttcctg	ctgg	cctgcg	tg	aactgt	gata	tttat	catca	540
caaaatt	tttg	cctgtt	ttgt	ttccg	aaagc	ttgcc	aaaac	aggaa	agaag	aagaaa	agag	600
attagt	tata	tcaaa	agcct	gaagt	ggaat	gactga	aaaga	tgggac	tcct	ccttt	atttc	660
agcatg	gagg	gtttta	aatg	gaggat	ttcc	ttttc	cctgt	gacaaa	acat	ctttt	acta	720
cttacct	tgt	taagaca	aaa	tttatt	ttcc	agggat	ttta	tacgt	acttt	agttg	gaatt	780
attctat	gtc	aatgat	tttt	aagct	atgaa	aaatac	aatg	ggggg	aaagga	tagcat	tttg	840
agatata	acct	aatgtt	aaat	gacgag	ttac	tggtat	gcagc	acgcca	acat	ggcac	atgta	900
tacatat	gta	gcta	acctca	cgttgt	gcac	atgtac	cccta	aaactt	aaa	tataat	ttta	960

aaaaagcaaa ggggtaccg 978

<210> 119
<211> 20
<212> DNA
<213> H. sapiens

<400> 119
catgcaccta ttcagactgt 20

<210> 120
<211> 20
<212> DNA
<213> H. sapiens

<400> 120
tgggtgtcct gtagtagtga 20

<210> 121
<211> 25
<212> DNA
<213> H. sapiens

<400> 121
attgattttt cctcagatat aagta 25

<210> 122
<211> 22
<212> DNA
<213> H. sapiens

<400> 122
tcataatttc ccttaaaaac ac 22

<210> 123
<211> 22
<212> DNA
<213> H. sapiens

<400> 123
atatgtttgg gtatgttatt cc 22

<210> 124
<211> 18
<212> DNA
<213> H. sapiens

<400> 124
ccatattccc ctcactct 18

<210> 125
<211> 23
<212> DNA
<213> H. sapiens

<400> 125
atacctgcat attcaaataa caa 23

<210> 126
<211> 18
<212> DNA
<213> H. sapiens

<400> 126 tatccagcca ttccttct	18
<210> 127 <211> 22 <212> DNA <213> H. sapiens	
<400> 127 agttttgtgg gtataatgtt ac	22
<210> 128 <211> 19 <212> DNA <213> H. sapiens	
<400> 128 aaacgggtta aaattcata	19
<210> 129 <211> 25 <212> DNA <213> H. sapiens	
<400> 129 tcataccttg taattaataa ttttg	25
<210> 130 <211> 20 <212> DNA <213> H. sapiens	
<400> 130 cgggttaaaa ttcatttca	20
<210> 131 <211> 18 <212> DNA <213> H. sapiens	
<400> 131 tcatgccaat tcagtgac	18
<210> 132 <211> 17 <212> DNA <213> H. sapiens	
<400> 132 accctccatg ctgaaat	17
<210> 133 <211> 21 <212> DNA <213> H. sapiens	
<400> 133 tcaaagacca tccatagact t	21
<210> 134 <211> 19	

<212> DNA
<213> H. sapiens

<400> 134
ggagtcccat ctttcagtc 19

<210> 135
<211> 25
<212> DNA
<213> H. sapiens

<400> 135
attgattttt cctcagatat aagta 25

<210> 136
<211> 19
<212> DNA
<213> H. sapiens

<400> 136
atttactggc attgacaag 19

<210> 137
<211> 25
<212> DNA
<213> H. sapiens

<400> 137
attgattttt cctcagatat aagta 25

<210> 138
<211> 22
<212> DNA
<213> H. sapiens

<400> 138
tgtacagaaa gggatatgtta aa 22

<210> 139
<211> 20
<212> DNA
<213> H. sapiens

<400> 139
aaaaatkatt tggaagattc 20

<210> 140
<211> 22
<212> DNA
<213> H. sapiens

<400> 140
tcataatttc ccttaaaaaac ac 22

<210> 141
<211> 23
<212> DNA
<213> H. sapiens

<400> 141
atacctgcat attcaaataa caa 23

<210> 142
<211> 18
<212> DNA
<213> H. sapiens

<400> 142
tatccagcca ttccttct 18

<210> 143
<211> 25
<212> DNA
<213> H. sapiens

<400> 143
tcataccttg taattaataa ttttg 25

<210> 144
<211> 20
<212> DNA
<213> H. sapiens

<400> 144
cgggttaaaa ttcatttca 20

<210> 145
<211> 21
<212> DNA
<213> H. sapiens

<400> 145
tcaaagacca tccatagact t 21

<210> 146
<211> 19
<212> DNA
<213> H. sapiens

<400> 146
ggagtcccat ctttcagtc 19

<210> 147
<211> 20
<212> DNA
<213> H. sapiens

<400> 147
tgatacagct cagttgttac 20

<210> 148
<211> 20
<212> DNA
<213> H. sapiens

<400> 148
tgatacagct cggttgttac 20

<210> 149
<211> 20
<212> DNA
<213> H. sapiens

<400> 149

tggtgacatc ttcggcttct	20
<210> 150	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 150	
tggtgacatc gtcggcttct	20
<210> 151	
<211> 23	
<212> DNA	
<213> H. sapiens	
<400> 151	
ctttaactaa aaatgatttg gaa	23
<210> 152	
<211> 23	
<212> DNA	
<213> H. sapiens	
<400> 152	
ctttaactaa aaattatttg gaa	23
<210> 153	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 153	
tttaacatac cctttctgta ca	22
<210> 154	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 154	
tttaacatac cctttccgta ca	22
<210> 155	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 155	
ttggaggact tcactgtaaa cc	22
<210> 156	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 156	
ttggaggact tcagtgtaaa cc	22
<210> 157	
<211> 23	
<212> DNA	
<213> H. sapiens	

<400> 157	
tatgaggcga tctaccatgg gat	23
<210> 158	
<211> 23	
<212> DNA	
<213> H. sapiens	
<400> 158	
tatgaggcaa tctaccatgg gat	23
<210> 159	
<211> 24	
<212> DNA	
<213> H. sapiens	
<400> 159	
cccttgtttg cggatcaaca tgat	24
<210> 160	
<211> 24	
<212> DNA	
<213> H. sapiens	
<400> 160	
cccttgtttg tggatcaaca tgat	24
<210> 161	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 161	
aaagagaatg tcatgaaatt at	22
<210> 162	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 162	
aaagagaata tcatgaaatt at	22
<210> 163	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 163	
gcttgccaaa acaggaaaga a	21
<210> 164	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 164	
gcttgccaaa aaaggaaaga a	21

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/16675

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LEVESQUE E. ET AL.,: "Isolation and characterization of UGT2B15 : a UDP-Glucuronosyltransferase encoded by a polymorphic gene"</p> <p>PHARMACOGENETICS, vol. 7, no. 4, - August 1997 (1997-08) pages 317-325, XP000852552 cited in the application see whole doc. esp. results p.320 ff.</p> <p>---</p> <p>-/--</p>	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

8 November 1999

Date of mailing of the international search report

22/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo rd,
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/16675

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>RITTER J.K. ET AL.,: "Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells"</p> <p>J. BIOL. CHEMISTRY, vol. 265, no. 14, - 15 May 1990 (1990-05-15) pages 7900-7906, XP002121919 the whole document</p>	1-3
X	<p>JIN. C_J. ET AL.,: "cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily"</p> <p>BIOCHEM. BIOPHYS. RESEARCH COMMUNICATIONS, vol. 194, no. 1, - 15 July 1993 (1993-07-15) pages 496-503, XP002121839 cited in the application the whole document</p>	1-3
X	<p>WO 92 12987 A (US) 6 August 1992 (1992-08-06) see whole doc. esp. claims and summary</p>	1-10
A	<p>RITTER J.K. ET AL.,: "Cloning of two human liver bilirubin UDP-glucuronosyl-transferase cDNAs with expression in COS-1 cells"</p> <p>J. BIOL. CHEMISTRY, vol. 266, no. 2, - 15 January 1991 (1991-01-15) pages 1043-1047, XP002121838 the whole document</p>	1-3
A	<p>GREEN M D ET AL: "STABLE EXPRESSION OF A HUMAN LIVER UDP-GLUCURONOSYLTRANSFERASE (UGT2B15) WITH ACTIVITY TOWARD STEROID AND XENOBIOTIC SUBSTRATES"</p> <p>DRUG METABOLISM AND DISPOSITION, vol. 22, no. 5, 1 September 1994 (1994-09-01), pages 799-805, XP002039718 ISSN: 0090-9556 cited in the application</p>	
A	<p>CIOTTI ET AL: "GENETIC POLYMORPHISM IN THE HUMAN UGT1A6 (PLANAR PHENOL) UDP-GLUCURONOSYLTRANSFERASE: PHARMACOLOGICAL IMPLICATIONS"</p> <p>PHARMACOGENETICS, vol. 7, no. 7, 1997, pages 485-495 495, XP002113205 ISSN: 0960-314X the whole document</p>	

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 99/16675

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	DE WILDT S.N. ET AL.,: "Glucuronidation in humans" CLIN. PHARMACOKINETICS, vol. 36, no. 6, - June 1999 (1999-06) pages 439-452, XP002121840 the whole document ---	
P,X	LEVESQUE E. ET AL.,: "Characterization and substrate specificity of UGT2B4: a UDP-glucuronosyltransferase encoded by a polymorphic gene" PHARMACOGENETICS, vol. 9, no. 2, - April 1999 (1999-04) pages 207-216, XP000852554 the whole document ---	1-10
P,X	MACLEOD S.L. ET AL.,: "a genetic polymorphism in UGT2B15 as a risk factor for breast and prostate cancer" PROC. AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, - March 1999 (1999-03) pages 243-244, XP002121841 the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/US 99/16675

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9212987 A	06-08-1992	AU 1227892 A	27-08-1992